form10q.htm
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
10-Q
x
|
QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
|
For the
quarterly period ended March 31, 2008
|
TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
|
For the
transition period from
to
Commission
file number 001-31922
TEMPUR-PEDIC
INTERNATIONAL INC.
(Exact
name of registrant as specified in its charter)
|
|
|
Delaware
|
|
33-1022198
|
(State
or other jurisdiction of
incorporation
or organization)
|
|
(I.R.S.
Employer
Identification
No.)
|
1713
Jaggie Fox Way
Lexington,
Kentucky 40511
(Address,
including zip code, of principal executive offices)
Registrant’s
telephone number, including area code: (800) 878-8889
Indicate
by check mark whether the registrant (1) has filed all reports required to be
filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required
to file such reports), and (2) has been subject to such filing requirements for
the past 90 days. Yes x No
Indicate
by check mark whether the Registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer, or a smaller reporting
company. See definitions of “large accelerated filer,” “accelerated filer” and
“smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check
one):
Large
accelerated filer x Accelerated
filer o Non-accelerated
filer o
(Do not
check if a smaller reporting company) Smaller reporting company o
Indicate
by check mark whether the registrant is a shell company (as defined in Rule
12b-2 of the Exchange Act.): Yes ¨ No x
The
number of shares outstanding of the registrant’s common stock as of April 30,
2008 was 74,673,553 shares.
|
|
|
|
|
|
|
|
|
Page
|
|
|
3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4
|
|
|
|
|
5
|
|
|
|
|
6
|
|
|
|
|
7
|
|
|
|
|
|
|
|
18
|
|
|
|
|
|
|
|
25
|
|
|
|
|
|
|
|
26
|
|
|
|
|
|
|
|
|
|
|
|
|
27
|
|
|
|
|
|
|
|
28
|
|
|
|
|
|
|
|
29
|
|
|
|
|
|
|
|
29
|
|
|
|
|
|
|
|
29
|
|
|
|
|
|
|
|
29
|
|
|
|
|
|
|
|
29
|
|
|
|
|
30
|
|
|
|
This
quarterly report on Form 10-Q, including the information incorporated by
reference herein, contains “forward-looking statements” within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, which include information
concerning our plans, objectives, goals, strategies, future events, future
revenues or performance, capital expenditures, the impact of the adoption of
recently issued accounting pronouncements, the putative securities and antitrust
class action lawsuits, related and other lawsuits and pending tax assessments,
expand market share and attract sales from the standard mattress market, to
expand business within established accounts and into under-penetrated markets,
reduce costs and improve manufacturing productivity, the impact of net operating
losses, the vertical integration of our business, our ability to source raw
materials effectively, the development, rollout and market acceptance of new
products, including our new product launch, increase in brand awareness, growth
in our Healthcare segment, the impact of the macroeconomic environment on our
business, expected sources of cash flow, the impact of the stock repurchase
program and other information that is not historical information. Many of these
statements appear, in particular, under the heading “Management’s Discussion and
Analysis of Financial Condition and Results of Operations” in ITEM 2 of Part I
of this report. When used in this report, the words “estimates,” “expects,”
“anticipates,” “projects,” “plans,” “intends,” “believes” and variations of such
words or similar expressions are intended to identify forward-looking
statements. These forward-looking statements are based upon our current
expectations and various assumptions. There can be no assurance that we will
realize our expectations or that our beliefs will prove
correct.
There
are a number of risks and uncertainties that could cause our actual results to
differ materially from the forward-looking statements contained in this report.
Important factors that could cause our actual results to differ materially from
those expressed as forward-looking statements are set forth in this report,
including under the heading “Risk Factors” under ITEM IA of Part II of this
report and under the heading “Risk Factors” under ITEM 1A of Part 1 of our Form
10-K for the year ended December 31, 2007. There may be other factors that may
cause our actual results to differ materially from the forward-looking
statements.
All
forward-looking statements attributable to us apply only as of the date of this
report and are expressly qualified in their entirety by the cautionary
statements included in this report. Except as may be required by law, we
undertake no obligation to publicly update or revise any of the forward-looking
statements, whether as a result of new information, future events, or
otherwise.
When
used in this report, except as specifically noted otherwise, the term
“Tempur-Pedic International” refers to Tempur-Pedic International Inc. only, and
the terms “Company,” “we,” “our,” “ours” and “us” refer to Tempur-Pedic
International Inc. and its consolidated subsidiaries.
ITEM 1.
|
FINANCIAL
STATEMENTS
|
(In
thousands, except per share amounts)
(Unaudited)
|
Three
Months Ended
|
|
|
March
31,
|
|
|
|
2008
|
|
|
|
2007
|
|
Net
sales
|
$
|
247,222
|
|
|
$
|
266,032
|
|
Cost
of sales
|
|
139,141
|
|
|
|
138,373
|
|
Gross
profit
|
|
108,081
|
|
|
|
127,659
|
|
Selling
and marketing expenses
|
|
53,163
|
|
|
|
48,480
|
|
General
and administrative expenses and other
|
|
25,585
|
|
|
|
25,425
|
|
Operating
income
|
|
29,333
|
|
|
|
53,754
|
|
|
|
|
|
|
|
|
|
Other
expense, net:
|
|
|
|
|
|
|
|
Interest
expense, net
|
|
(7,691
|
)
|
|
|
(6,861
|
)
|
Other
expense, net
|
|
(1,019
|
)
|
|
|
(289
|
)
|
Total
other expense
|
|
(8,710
|
)
|
|
|
(7,150
|
)
|
|
|
|
|
|
|
|
|
Income
before income taxes
|
|
20,623
|
|
|
|
46,604
|
|
Income
tax provision
|
|
7,109
|
|
|
|
16,824
|
|
Net
income
|
$
|
13,514
|
|
|
$
|
29,780
|
|
|
|
|
|
|
|
|
|
Earnings
per common share:
|
|
|
|
|
|
|
|
Basic
|
$
|
0.18
|
|
|
$
|
0.35
|
|
Diluted
|
$
|
0.18
|
|
|
$
|
0.35
|
|
|
|
|
|
|
|
|
|
Cash
dividend per common share
|
$
|
0.08
|
|
|
$
|
0.06
|
|
|
|
|
|
|
|
|
|
Weighted
average common shares outstanding:
|
|
|
|
|
|
|
|
Basic
|
|
74,591
|
|
|
|
83,947
|
|
Diluted
|
|
75,188
|
|
|
|
85,775
|
|
See
accompanying Notes to Condensed Consolidated Financial
Statements.
TEMPUR-PEDIC
INTERNATIONAL INC. AND SUBSIDIARIES
(In
thousands, except per share amounts)
|
March
31,
2008
|
|
December
31,
2007
|
|
(Unaudited)
|
|
|
ASSETS
|
|
|
|
|
|
|
|
Current
Assets:
|
|
|
|
|
|
|
|
Cash
and cash equivalents
|
$
|
46,567
|
|
|
$
|
33,315
|
|
Accounts
receivable, net
|
|
152,581
|
|
|
|
163,730
|
|
Inventories
|
|
112,001
|
|
|
|
106,533
|
|
Prepaid
expenses and other current assets
|
|
15,116
|
|
|
|
11,133
|
|
Deferred
income taxes
|
|
13,922
|
|
|
|
11,924
|
|
Total
Current Assets
|
|
340,187
|
|
|
|
326,635
|
|
|
|
|
|
|
|
|
|
Property,
plant and equipment, net
|
|
208,703
|
|
|
|
208,370
|
|
Goodwill
|
|
198,372
|
|
|
|
198,286
|
|
Other
intangible assets, net
|
|
68,028
|
|
|
|
68,755
|
|
Deferred
financing costs and other non-current assets, net
|
|
5,345
|
|
|
|
4,386
|
|
Total
Assets
|
$
|
820,635
|
|
|
$
|
806,432
|
|
|
|
|
|
|
|
|
|
LIABILITIES
AND STOCKHOLDERS’ EQUITY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current
Liabilities:
|
|
|
|
|
|
|
|
Accounts
payable
|
$
|
56,332
|
|
|
$
|
56,206
|
|
Accrued
expenses and other
|
|
65,102
|
|
|
|
66,080
|
|
Income
taxes payable
|
|
1,350
|
|
|
|
4,060
|
|
Current
portion of long-term debt
|
|
277
|
|
|
|
288
|
|
Total
Current Liabilities
|
|
123,061
|
|
|
|
126,634
|
|
|
|
|
|
|
|
|
|
Long-term
debt
|
|
596,792
|
|
|
|
601,756
|
|
Deferred
income taxes
|
|
30,248
|
|
|
|
29,645
|
|
Other
non-current liabilities
|
|
294
|
|
|
|
259
|
|
Total
Liabilities
|
|
750,395
|
|
|
|
758,294
|
|
|
|
|
|
|
|
|
|
Commitments
and contingencies—see Note 7
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders’
Equity:
|
|
|
|
|
|
|
|
Common
stock—$.01 par value; 300,000 shares authorized; 99,215
shares issued as of March 31, 2008 and December
31, 2007
|
|
992
|
|
|
|
992
|
|
Additional
paid in capital
|
|
284,779
|
|
|
|
283,564
|
|
Retained
earnings
|
|
249,313
|
|
|
|
241,812
|
|
Accumulated
other comprehensive income
|
|
25,341
|
|
|
|
13,550
|
|
Treasury
stock, at cost; 24,541 and 24,681 shares as of March 31, 2008 and December
31, 2007, respectively
|
|
(490,185
|
)
|
|
|
(491,780
|
)
|
Total
Stockholders’ Equity
|
|
70,240
|
|
|
|
48,138
|
|
|
|
|
|
|
|
|
|
Total
Liabilities and Stockholders’ Equity
|
$
|
820,635
|
|
|
$
|
806,432
|
|
See
accompanying Notes to Condensed Consolidated Financial
Statements.
TEMPUR-PEDIC
INTERNATIONAL INC. AND SUBSIDIARIES
(In
thousands)
(Unaudited)
|
Three
Months Ended
March
31,
|
|
2008
|
|
2007
|
|
|
|
|
CASH
FLOWS FROM OPERATING ACTIVITIES:
|
|
|
|
|
|
|
|
Net
income
|
$
|
13,514
|
|
|
$
|
29,780
|
|
Adjustments
to reconcile net income to net cash provided by operating
activities:
|
|
|
|
|
|
|
|
Depreciation
and amortization
|
|
8,334
|
|
|
|
8,645
|
|
Amortization
of deferred financing costs
|
|
185
|
|
|
|
287
|
|
Amortization
of stock-based compensation
|
|
1,979
|
|
|
|
1,791
|
|
Allowance
for doubtful accounts
|
|
985
|
|
|
|
2,129
|
|
Deferred
income taxes
|
|
(1,158
|
)
|
|
|
(2,082
|
)
|
Foreign
currency adjustments
|
|
1,156
|
|
|
|
301
|
|
Loss
(gain) on sale of equipment and other
|
|
41
|
|
|
|
(26
|
)
|
Changes
in operating assets and liabilities:
|
|
|
|
|
|
|
|
Accounts
receivable
|
|
14,304
|
|
|
|
(4,902
|
)
|
Inventories
|
|
(2,252
|
)
|
|
|
(11,286
|
)
|
Prepaid
expenses and other current assets
|
|
(4,583
|
)
|
|
|
(11,339
|
)
|
Accounts
payable
|
|
(2,547
|
)
|
|
|
8,655
|
|
Accrued
expenses and other
|
|
(2,354
|
)
|
|
|
3,212
|
|
Income
taxes
|
|
(2,696
|
)
|
|
|
12,576
|
|
Excess
tax benefit from stock based compensation
|
|
(323
|
)
|
|
|
(9,166
|
)
|
Net
cash provided by operating activities
|
|
24,585
|
|
|
|
28,575
|
|
|
|
|
|
|
|
|
|
CASH
FLOWS FROM INVESTING ACTIVITIES:
|
|
|
|
|
|
|
|
Payments
for trademarks and other intellectual property
|
|
(182
|
)
|
|
|
(258
|
)
|
Purchases
of property, plant and equipment
|
|
(2,793
|
)
|
|
|
(2,430
|
)
|
Acquisition
of businesses
|
|
(1,498
|
)
|
|
|
(1,005
|
)
|
Proceeds
from sale of equipment
|
|
37
|
|
|
|
24
|
|
Net
cash used by investing activities
|
|
(4,436
|
)
|
|
|
(3,669
|
)
|
|
|
|
|
|
|
|
|
CASH
FLOWS FROM FINANCING ACTIVITIES:
|
|
|
|
|
|
|
|
Proceeds
from long-term revolving credit facility
|
|
7,221
|
|
|
|
77,571
|
|
Repayments
of long-term revolving credit facility
|
|
(12,233
|
)
|
|
|
(61,047
|
)
|
Repayments
of Series A Industrial Revenue Bonds
|
|
—
|
|
|
|
(1,920
|
)
|
Repayments
of long-term debt
|
|
(77
|
)
|
|
|
(9,375
|
)
|
Common
stock issued, including reissuances of Treasury stock
|
|
498
|
|
|
|
5,294
|
|
Excess
tax benefit from stock based compensation
|
|
323
|
|
|
|
9,166
|
|
Treasury
stock purchased
|
|
—
|
|
|
|
(39,181
|
)
|
Dividends
paid to stockholders
|
|
(5,965
|
)
|
|
|
(5,106
|
)
|
Payments
for deferred financing costs
|
|
(14
|
)
|
|
|
(51
|
)
|
Net
cash used by financing activities
|
|
(10,247
|
)
|
|
|
(24,649
|
)
|
|
|
|
|
|
|
|
|
NET
EFFECT OF EXCHANGE RATE CHANGES ON CASH
|
|
3,350
|
|
|
|
729
|
|
|
|
|
|
|
|
|
|
Increase
in cash and cash equivalents
|
|
13,252
|
|
|
|
986
|
|
|
|
|
|
|
|
|
|
CASH
AND CASH EQUIVALENTS, beginning of period
|
|
33,315
|
|
|
|
15,788
|
|
|
|
|
|
|
|
|
|
CASH
AND CASH EQUIVALENTS, end of period
|
$
|
46,567
|
|
|
$
|
16,774
|
|
|
|
|
|
|
|
|
|
Supplemental
cash flow information:
|
|
|
|
|
|
|
|
Cash
paid during the period for:
|
|
|
|
|
|
|
|
Interest
|
$
|
7,589
|
|
|
$
|
5,894
|
|
Income
taxes, net of refunds
|
$
|
10,737
|
|
|
$
|
6,409
|
|
See
accompanying Notes to Condensed Consolidated Financial Statements.
TEMPUR-PEDIC
INTERNATIONAL INC. AND SUBSIDIARIES
(In
thousands, except per share amounts)
(1)
Summary of Significant Accounting Policies
(a) Basis of Presentation and
Description of Business—Tempur-Pedic International Inc., a Delaware
corporation, together with its subsidiaries is a U.S.-based, multinational
company. The term “Tempur-Pedic International” refers to Tempur-Pedic
International Inc. only, and the term “Company” refers to Tempur-Pedic
International Inc. and its consolidated subsidiaries.
The Company
manufactures, markets, and sells pillows, mattresses, and other related
products. The Company manufactures essentially all its pressure-relieving
TEMPUR®
products at three manufacturing facilities, with one located in Denmark
and two in the U.S. The Company has sales distribution subsidiaries operating in
the U.S., Europe, and Asia Pacific and has third party distribution arrangements
in certain other countries where it does not have subsidiaries. The Company
sells its products through four sales channels: Retail, Direct, Healthcare, and
Third party.
The
accompanying unaudited Condensed Consolidated Financial Statements have been
prepared in accordance with the instructions to Form 10-Q and Article 10 of
Regulation S-X and do not include all of the information and disclosures
required by generally accepted accounting principles in the United States (U.S.
GAAP) for complete financial statements. Accordingly, these unaudited Condensed
Consolidated Financial Statements should be read in conjunction with the
consolidated financial statements of the Company and related footnotes for the
year ended December 31, 2007, included in the Company’s Annual Report on Form
10-K. The balance sheet as of December 31, 2007 has been derived from the
audited consolidated financial statements as of that date but does not include
all of the information and footnotes required by U.S. GAAP for complete
financial statements.
The results
of operations for the interim periods are not necessarily indicative of results
of operations for a full year. It is the opinion of management that all
necessary adjustments for a fair presentation of the results of operations for
the interim periods have been made and are of a recurring nature unless
otherwise disclosed herein.
(b) Reclassifications—Certain
prior period amounts have been reclassified to conform to the 2008 presentation
including the presentation of General and administrative and other
expenses which includes Research and development expenses previously broken out
separately in the Condensed Consolidated Statements of Income. These changes do
not materially affect previously reported subtotals within the Consolidated
Financial Statements for any previous period presented.
(c) Basis of Consolidation—The
accompanying financial statements include the accounts of Tempur-Pedic
International and its subsidiaries. All subsidiaries are wholly owned.
Intercompany balances and transactions have been eliminated.
(d) Use of Estimates—The
preparation of financial statements in conformity with U.S. GAAP requires
management to make estimates and assumptions that affect the reported amounts of
assets and liabilities and disclosure of contingent assets and liabilities at
the date of the financial statements and the reported amounts of revenues and
expenses during the reporting period. Actual results could differ from those
estimates.
(e) Foreign Currency
Translation—Assets and liabilities of non-U.S. subsidiaries, whose
functional currency is the local currency, are translated at period-end exchange
rates. Income and expense items are translated at the average rates of exchange
prevailing during the period. The adjustment resulting from translating the
financial statements of foreign subsidiaries is included in Accumulated other
comprehensive income, a component of Stockholders’ Equity.
(f) Financial Instruments and
Hedging—Derivative financial instruments are used within the normal
course of business and are used to manage foreign currency exchange rate risk.
These instruments are short term in nature and are subject to fluctuations in
foreign exchange rates and credit risk. Credit risk is managed through the
selection of sound financial institutions as counterparties. The changes in fair
market value of foreign exchange derivatives are recognized currently through
earnings.
The carrying
value of Cash and cash equivalents, Accounts receivable, and Accounts payable
approximate fair value because of the short-term maturity of those instruments.
Borrowings under the 2005 Senior Credit Facility (as defined in Note (4)(b)) and
under the Bonds (as defined in Note (4)(c)) are at variable interest rates and
accordingly their carrying amounts approximate fair value.
(g) Cash and Cash
Equivalents—Cash and cash equivalents consist of all investments with
initial maturities of three months or less.
(h) Inventories—Inventories are
stated at the lower of cost or market, determined by the first-in, first-out
method, and consist of the following:
|
|
March
31,
2008
|
|
|
December
31,
2007
|
|
Finished
goods
|
|
$ |
82,392 |
|
|
$ |
75,692 |
|
Work-in-process
|
|
|
8,623 |
|
|
|
11,135 |
|
Raw
materials and supplies
|
|
|
20,986 |
|
|
|
19,706 |
|
|
|
$ |
112,001 |
|
|
$ |
106,533 |
|
(i) Long Lived Assets—In
accordance with Statement of Financial Accounting Standards (SFAS) 144,
“Accounting for the Impairment or Disposal of Long-lived Assets,” long-lived
assets are reviewed for impairment whenever events or changes in circumstances
indicate that the carrying amount of an asset may not be recoverable.
Recoverability of long-lived assets is assessed by a comparison of the carrying
amount of the asset to the estimated future undiscounted net cash flows expected
to be generated by the asset. If estimated future undiscounted net cash flows
are less than the carrying amount of the asset or group of assets, the asset is
considered impaired and an expense is recorded in an amount required to reduce
the carrying amount of the asset to its then fair value.
(j) Goodwill and Other Intangible
Assets—Intangible assets with estimable useful lives are amortized over
their respective estimated useful lives to their estimated residual values and
reviewed for impairment. The Company performs an annual impairment test on all
existing goodwill and other indefinite lived assets in the fourth quarter of
each year. The Company performed the annual impairment test in the fourth
quarter of 2007 and determined there were no indicators of impairment as of
December 31, 2007. If facts and circumstances lead the Company’s management to
believe goodwill or other indefinite lived assets may be impaired, the Company
will evaluate the extent to which the related cost is recoverable by
comparing the future discounted cash flows estimated to be associated with that
asset to the asset’s carrying amount and write-down that carrying amount to fair
value to the extent necessary.
The following
table summarizes information relating to the Company’s Other intangible
assets:
|
|
|
|
|
March
31, 2008
|
|
|
December
31, 2007
|
|
|
|
Useful
|
|
|
Gross
|
|
|
|
|
|
Net
|
|
|
Gross
|
|
|
|
|
|
Net
|
|
|
|
Lives
|
|
|
Carrying
|
|
|
Accumulated
|
|
|
Carrying
|
|
|
Carrying
|
|
|
Accumulated
|
|
|
Carrying
|
|
|
|
(Years)
|
|
|
Amount
|
|
|
Amortization
|
|
|
Amount
|
|
|
Amount
|
|
|
Amortization
|
|
|
Amount
|
|
Unamortized
indefinite life
intangible assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Trademarks
|
|
|
|
|
$ |
55,000 |
|
|
$ |
— |
|
|
$ |
55,000 |
|
|
$ |
55,000 |
|
|
$ |
— |
|
|
$ |
55,000 |
|
Amortized
intangible assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Technology
|
|
|
10 |
|
|
$ |
16,000 |
|
|
$ |
8,667 |
|
|
$ |
7,333 |
|
|
$ |
16,000 |
|
|
$ |
8,267 |
|
|
$ |
7,733 |
|
Patents
& Other
Trademarks
|
|
|
5-20 |
|
|
|
11,021 |
|
|
|
7,564 |
|
|
|
3,457 |
|
|
|
11,233 |
|
|
|
7,533 |
|
|
|
3,700 |
|
Customer
database
|
|
|
5 |
|
|
|
4,923 |
|
|
|
4,381 |
|
|
|
542 |
|
|
|
4,868 |
|
|
|
4,334 |
|
|
|
534 |
|
Foam
formula
|
|
|
10 |
|
|
|
3,700 |
|
|
|
2,004 |
|
|
|
1,696 |
|
|
|
3,700 |
|
|
|
1,912 |
|
|
|
1,788 |
|
Total
|
|
|
|
|
|
$ |
90,644 |
|
|
$ |
22,616 |
|
|
$ |
68,028 |
|
|
$ |
90,801 |
|
|
$ |
22,046 |
|
|
$ |
68,755 |
|
Amortization
expense relating to intangible assets for the Company was $611 and $1,034 for
the three months ended March 31, 2008 and March 31, 2007,
respectively.
The changes
in the carrying amount of Goodwill for the three months ended March 31,
2008 are as follows:
Balance
as of December 31, 2007
|
|
$ |
198,286 |
|
Goodwill
acquired during the period
|
|
|
616 |
|
Foreign
currency translation adjustments and other
|
|
|
(530 |
) |
Balance
as of March 31, 2008
|
|
$ |
198,372 |
|
Goodwill as
of March 31, 2008 and December 31, 2007 has been allocated to the Domestic and
International segments as follows:
|
|
March 31,
2008
|
|
|
December
31,
2007
|
|
Domestic
|
|
$ |
89,929 |
|
|
$ |
89,929 |
|
International
|
|
|
108,443 |
|
|
|
108,357 |
|
|
|
$ |
198,372 |
|
|
$ |
198,286 |
|
On February
1, 2008, the Company acquired its third party distributor in New Zealand. The
total purchase price was approximately $1,438. The assets purchased were
initially valued at approximately $948 and include inventory and fixed assets,
among other assets. The remainder of the purchase price was allocated to
Goodwill.
(k) Accrued Sales Returns—
Estimated sales returns are provided at the time of sale based on historical
sales channel return rates. The level of sales returns differs by channel with
the Direct channel typically experiencing the highest rate of
return. Estimated future obligations related to these products are
provided by a reduction of sales in the period in which the revenue is
recognized. The Company allows product returns up to 120 days following a sale
through certain sales channels and on certain products. Accrued sales returns
are included in Accrued expenses and other in the accompanying Condensed
Consolidated Balance Sheets.
The Company
had the following activity for sales returns from December 31, 2007 to March 31,
2008:
Balance
as of December 31, 2007
|
|
$ |
5,463 |
|
Amounts
accrued
|
|
|
12,616 |
|
Returns
charged to accrual
|
|
|
(13,125 |
) |
Balance
as of March 31, 2008
|
|
$ |
4,954 |
|
(l) Warranties—The Company
provides a 20-year warranty for U.S. sales and a 15-year warranty for non-U.S.
sales on mattresses, each prorated for the last 10 years. The Company also
provides a 2-year to 3-year warranty on pillows. Estimated future obligations
related to these products are charged to operations in the period in which the
related revenue is recognized. Warranties are included in Accrued expenses and
other in the accompanying Condensed Consolidated Balance Sheets.
The Company
had the following activity for warranties from December 31, 2007 to March 31,
2008:
Balance
as of December 31, 2007
|
|
$ |
3,425 |
|
Amounts
accrued
|
|
|
1,103 |
|
Warranties
charged to accrual
|
|
|
(697 |
) |
Balance
as of March 31, 2008
|
|
$ |
3,831 |
|
(m) Income Taxes—Deferred tax
assets and liabilities are recognized for the future tax consequences
attributable to temporary differences between the financial statement carrying
amounts of existing assets and liabilities and their respective tax bases.
Deferred tax assets and liabilities are measured using enacted tax rates
expected to apply to taxable income in the years in which those temporary
differences are expected to be recovered or settled. The Company is regularly
under audit by tax authorities around the world. The Company accounts for
uncertain foreign and domestic tax positions as required by Financial Accounting
Standards Board (FASB) Interpretation No. 48, “Accounting for Uncertainty in
Income Taxes” (FIN 48) according to the facts and circumstances in the various
regulatory environments.
(n) Accumulated Other Comprehensive
Income— The adjustment resulting from translating the financial
statements of foreign subsidiaries is included in Accumulated other
comprehensive income, a component of Stockholders’ Equity. As of March 31, 2008,
Accumulated other comprehensive income was $25,341, which consists solely of
foreign currency translation adjustments.
(o) Revenue Recognition—Sales of
products are recognized when the products are shipped to customers and the risks
and rewards of ownership are transferred. The Company extends volume discounts
to certain customers and reflects these amounts as a reduction of Net sales. No
collateral is required on sales made in the normal course of business. The
allowance for doubtful accounts is the Company’s best estimate of the amount of
probable credit losses in the Company’s existing accounts receivable. The
Company determines the allowance based on historical write-off experience. The
Company regularly reviews the adequacy of its allowance for doubtful accounts.
Account balances are charged off against the allowance after all means of
collection have been exhausted and the potential for recovery is considered
remote. The allowance for doubtful accounts included in Accounts receivable, net
in the accompanying Condensed Consolidated Balance Sheets was $8,294 and $8,056
as of March 31, 2008 and December 31, 2007, respectively.
The Company
reflects all amounts billed to customers for shipping and handling in Net sales
and the costs incurred from shipping and handling product in Cost of sales.
Amounts included in Net sales for shipping and handling were approximately
$2,589 and $3,038 for the three months ended March 31, 2008 and March 31, 2007,
respectively. Amounts included in Cost of sales for shipping and
handling were approximately $20,665 and $20,497 for the three months ended
March 31, 2008 and March 31, 2007, respectively.
(p) Advertising Costs—The
Company expenses advertising costs as incurred except for production costs and
advance payments, which are deferred and expensed when advertisements run for
the first time. Direct response advance payments are deferred and are amortized
over the life of the program. Advertising costs charged to expense were
approximately $29,327 and $27,519 for the three months ended March 31, 2008 and
March 31, 2007, respectively. Advertising costs deferred and included
in Prepaid expenses and other current assets in the accompanying Condensed
Consolidated Balance Sheets were approximately $5,887 and $4,709 as of March 31,
2008 and December 31, 2007, respectively.
(q) Research and Development
Expenses—Research and development expenses for new products are expensed
as they are incurred. Research and development costs charged to expense were
approximately $1,833 and $1,115 for the three months ended March 31, 2008 and
March 31, 2007, respectively.
(r) Treasury Stock—The Board of
Directors may authorize share repurchases of the Company’s common stock (Share
Repurchase Authorizations). Share repurchases under these authorizations may be
made through open market transactions, negotiated purchase or otherwise, at
times and in such amounts as the Company, and a committee of the Board, deem
appropriate. Shares repurchased under Share Repurchase Authorizations are held
in treasury for general corporate purposes, including issuances under various
employee stock option plans. Treasury shares are accounted for under the cost
method and reported as a reduction of Stockholders’ Equity. Share Repurchase
Authorizations may be suspended, limited or terminated at any time without
notice.
(s) Stock-Based Compensation—The
Company accounts for share based payments as required by SFAS 123R “Share-Based
Payment” (SFAS 123R). SFAS 123R requires compensation expense relating to
share-based payments be recognized in the financial statements. The cost is
measured at the grant date, based on the calculated fair value of the award, and
is recognized as an expense over the vesting period of the equity
award.
(2)
Recently Issued Accounting Pronouncements
In
September 2006, the Financial Accounting Standards Board (FASB) issued
SFAS 157, “Fair Value Measurements,” (SFAS 157) which defines fair value,
establishes a framework for measuring fair value in U.S. GAAP, and expands
disclosure about fair value measurements to include the methods and assumptions
used to measure fair value and the effect of fair value measures on
earnings. SFAS 157 requires the fair value of an asset or liability
to be based on market-based measures which will reflect the credit risk of the
company. In February 2008, the FASB released FASB Staff Position No. SFAS 157-2,
“Effective Date of FASB
Statement No. 157,” which delays the effective date of SFAS 157 for
nonfinancial assets and liabilities until January 2009. Effective January
1, 2008, the Company adopted the provisions of SFAS 157 related to financial
assets and liabilities. SFAS 157 does not require new fair value
measurements. The adoption of SFAS 157 did not have an impact on the
Company’s financial position or operating results.
SFAS 157
establishes a three-level hierarchy for fair value measurements. The hierarchy
is based upon the transparency of inputs to the valuation of an asset or
liability as of the measurement date.
|
Level
1 – Valuation is based upon unadjusted quoted prices for identical assets
or liabilities in active markets.
|
|
Level
2 – Valuation is based upon quoted prices for similar assets and
liabilities in active markets, or other inputs that are observable for the
asset or liability, either directly or indirectly, for substantially
the full term of the financial
instruments.
|
|
Level
3 – Valuation is based upon other unobservable inputs that are significant
to the fair value measurements.
|
The
classification of fair value measurements within the hierarchy is based upon the
lowest level of input that is significant to the measurement. At
March 31, 2008, the Company had only foreign currency forward contracts recorded
at fair value. The fair values of the foreign currency forward contracts were
measured using significant other observable inputs (Level 3) and are valued by
reference to similar financial instruments, adjusted for restrictions and other
terms specific to the contracts. The fair value of the Company’s foreign
currency forward contracts was not material at March 31, 2008.
In December
2007, the FASB issued SFAS 141(R), “Business Combinations” (SFAS 141R), which
establishes principles and requirements for how the acquirer of a business
recognizes and measures in its financial statements the identifiable assets
acquired, the liabilities assumed, and any noncontrolling interest in the
acquired business. The statement also provides guidance for recognizing and
measuring the goodwill acquired in the business combination and determines what
information to disclose to enable users of the financial statements to evaluate
the nature and financial effects of the business combination. The Company is
evaluating the potential impact of adopting SFAS 141(R), which is effective for
fiscal years beginning after December 15, 2008.
(3)
Property, Plant and Equipment
Property,
plant and equipment, net consists of the following:
|
|
March
31, 2008
|
|
|
December 31, 2007
|
|
Land
and buildings
|
|
$
|
128,189
|
|
|
$
|
123,973
|
|
Machinery
and equipment, furniture and fixtures, and other
|
|
|
195,354
|
|
|
|
186,175
|
|
Construction
in progress
|
|
|
6,887
|
|
|
|
7,210
|
|
|
|
|
330,430
|
|
|
|
317,358
|
|
Total
accumulated depreciation
|
|
|
(121,727)
|
|
|
|
(108,988)
|
|
|
|
$
|
208,703
|
|
|
$
|
208,370
|
|
(4)
Long-term Debt
(a) Long-term Debt—Long-term debt
for the Company consists of the following:
|
|
March
31, 2008
|
|
|
December
31, 2007
|
|
2005
Senior Credit Facility:
|
|
|
|
|
|
|
Domestic
Long-Term Revolving Credit Facility payable to lenders, interest at
Index
Rate or LIBOR plus applicable margin (3.71% and 5.86% as of March 31, 2008
and
December 31, 2007, respectively), commitment through and due June 8,
2012
|
|
$ |
538,000 |
|
|
$ |
543,000 |
|
|
|
|
|
|
|
|
|
|
2005
Industrial Revenue Bonds:
|
|
|
|
|
|
|
|
|
Variable
Rate Industrial Revenue Bonds Series 2005A, interest rate determined
by remarketing agent not to exceed the lesser of (a) the highest rate
under state law or (b) 12%
per annum (2.70% and
5.10% as of March 31, 2008 and December 31, 2007, respectively), interest
due monthly through and due September 1, 2030
|
|
|
57,785 |
|
|
|
57,785 |
|
|
|
|
|
|
|
|
|
|
Other:
|
|
|
|
|
|
|
|
|
Mortgage
payable to a bank, secured by certain property, plant and equipment
and other assets, bearing fixed interest at 4.0% to 5.1%
|
|
|
1,284 |
|
|
|
1,259 |
|
|
|
|
597,069 |
|
|
|
602,044 |
|
Less:
Current portion
|
|
|
(277 |
) |
|
|
(288
|
) |
Long-term
debt
|
|
$ |
596,792 |
|
|
$ |
601,756 |
|
(b) Secured Credit Financing—On
October 18, 2005, the Company entered into a credit agreement (2005 Senior
Credit Facility) with a syndicate of banks. On February 8, 2006 and on December
13, 2006 the Company entered into amendments to its 2005 Senior Credit Facility,
which increased availability, adjusted one financial covenant and added an
option to increase the Domestic Revolver by an additional $50,000 at the
discretion of the Company. On February 22, 2007, the Company exercised the
option to increase the Domestic Revolver by an additional $50,000. On June 8,
2007, the Company entered into an amendment to its 2005 Senior Credit Facility
(Amendment No. 3), which increased availability, extinguished the foreign term
loan, eliminated the requirement to reduce the Domestic revolver commitment by
$3,000 each quarter, added an option to increase the Domestic Revolver by an
additional $100,000, eliminated the quarterly redemption of the Industrial
Revenue Bonds (as defined below) and adjusted certain covenants. In addition,
the maturity date of the 2005 Senior Credit Facility was extended from October
18, 2010 to June 8, 2012. In conjunction with Amendment No. 3, the Company
wrote-off $126 of deferred financing fees which were previously capitalized. On
August 6, 2007, the Company exercised the option to increase the Domestic
Revolver by an additional $100,000.
The 2005
Senior Credit Facility, as amended, consists of domestic and foreign credit
facilities that provide for the incurrence of indebtedness up to an aggregate
principal amount of $640,000. The domestic credit facility is a five-year,
$615,000 revolving credit facility (Domestic Revolver). The foreign credit
facility is a five-year $25,000 revolving credit facility (Foreign Revolver).
Both credit facilities bear interest at a rate equal to the 2005 Senior Credit
Facility’s applicable margin, as determined in accordance with a performance
pricing grid set forth in Amendment No. 3, plus one of the following indexes:
LIBOR and for U.S. dollar-denominated loans only, a base rate. The base rate of
U.S. dollar-denominated loans are defined as the higher of either the Bank of
America prime rate or the Federal Funds rate plus .50%. The Company also pays an
annual facility fee on the total amount of the 2005 Senior Credit
Facility. The facility fee is calculated based on the consolidated
leverage ratio and ranges from .125% to .25%.
The 2005
Senior Credit Facility is guaranteed by Tempur-Pedic International, as well as
certain other subsidiaries of Tempur-Pedic International, and is secured by
certain fixed and intangible assets of Dan Foam ApS and substantially all the
Company’s U.S. assets. The 2005 Senior Credit Facility contains certain
financial covenants and requirements affecting the Company, including a
consolidated interest coverage ratio and a consolidated leverage ratio. The
Company was in compliance with all covenants as of March 31, 2008.
At March 31,
2008, the Company had a total of $640,000 of long-term revolving credit
facilities under the 2005 Senior Credit Facility, which was comprised of the
$615,000 Domestic Revolver and the $25,000 Foreign Revolver (collectively, the
Revolvers). The Revolvers provide for the issuance of letters of credit which,
when issued, constitute usage and reduce availability under the Revolvers. The
aggregate amount of letters of credit outstanding under the Revolvers was
$64,796 at March 31, 2008. After giving effect to
letters of credit and $538,000 in borrowings under the Domestic Revolver, total
availability under the Revolvers was $37,204 at March 31, 2008.
(c) Industrial Revenue Bonds— On
October 27, 2005, Tempur Production USA, Inc., a subsidiary of Tempur-Pedic
International Inc. (Tempur Production), completed an industrial revenue bond
financing for the construction and equipping of Tempur Production’s new
manufacturing facility (the Project) located in Bernalillo County, New
Mexico. Under the terms of the financing, Bernalillo County was to
issue up to $75,000 of Series 2005A Taxable Variable Rate Industrial Revenue
Bonds (the Series A Bonds). The Series A Bonds are marketed to third
party qualified investors by a remarketing agent and secured by a letter of
credit issued under the Company’s Domestic Revolver. The Series A Bonds have a
final maturity date of September 1, 2030. The interest rate on the
Series A Bonds is a weekly rate set by the remarketing agent, in its sole
discretion, though the interest rate may not exceed the lesser of the highest
rate allowed under New Mexico law or 12% per annum. On October 27,
2005, Tempur Production made an initial draw of $53,925 on the Series A
Bonds. On June 1, 2007, the Company executed an additional advance of
$15,380 on the Series A Bonds. Upon completion of this draw, the Company
had a total of $59,705 outstanding under the Series A Bonds. The Company
used proceeds from the Bonds to pay down the Domestic Revolver, among other
things. No further advances are expected by the Company under the Series A
Bonds.
Bernalillo
County also agreed to issue up to $25,000 of Series 2005B Taxable Fixed Rate
Industrial Revenue Bonds (the Series B Bonds, and collectively with the Series A
Bonds, the Bonds). The Series B Bonds were sold to Tempur World LLC, are not
secured by the letter of credit described above, and will be held by Tempur
World, LLC, representing the Company’s equity in the Project. The Series B Bonds
have a final maturity date of September 1, 2030. The interest rate on the
Series B Bonds is fixed at 7.75%. On October 27, 2005, Tempur Production
made an initial draw of $17,975 under the Series B Bonds, which was transferred
to and used by Tempur World LLC to purchase Series B Bonds. On June 1, 2007, the
Company requested an additional advance of $5,127 on the Series B Bonds.
Proceeds of this draw were transferred to and used by Tempur World, LLC to
purchase the additional Series B Bonds. Upon completion of this draw, the
Company had a total of $23,103 outstanding under the Series B Bonds. No further
advances are expected by the Company under the Series B Bonds. The Company has
the right to offset the Series B Bonds against its investment in the Series B
Bonds, and accordingly, the amounts have been recorded net in the accompanying
Condensed Consolidated Balance Sheets.
On October
27, 2005, Tempur Production transferred its interest in the Project to
Bernalillo County, and Bernalillo County leased the Project back to Tempur
Production on a long-term basis with the right to purchase the Project for one
dollar when the Bonds are retired. Pursuant to the lease agreement,
Tempur Production will pay rent to Bernalillo County in an amount sufficient to
pay debt service on the Bonds and certain fees and expenses. The
Bonds are not general obligations of Bernalillo County, but are special, limited
obligations payable solely from bond proceeds, rent paid by Tempur Production
under the lease agreement, and other revenues. The substance of the
transaction is that Bernalillo County issued the Bonds on behalf of Tempur
Production. Therefore, the Company has recorded the obligation as
long-term debt of $57,785 in its Condensed Consolidated Balance Sheets as of
March 31, 2008 and December 31, 2007.
On April 1,
2008, Tempur Production redeemed all outstanding Series A Bonds in the amount of
$57,785. The redemption price plus accrued interest was funded by a
$58,000 borrowing under the Domestic Revolver. In connection with the
redemption, the letter of credit supporting the Bonds was retired, resulting in
no additional indebtedness outstanding under the 2005 Senior Credit Facility.
The Company will record a pretax charged of $354 as a Loss on extinguishment of
debt during the quarter ended June 30, 2008 related to the write-off of non-cash
deferred financing fees.
(5)
Stockholders’ Equity
(a) Capital Stock—Tempur-Pedic
International’s authorized shares of capital stock are 300,000 shares of common
stock and 10,000 shares of preferred stock. Subject to preferences that may be
applicable to any outstanding preferred stock, holders of the common stock are
entitled to receive ratably such dividends as may be declared from time to time
by the Board of Directors out of funds legally available for that purpose. In
the event of liquidation, dissolution, or winding up, the holders of the common
stock are entitled to share ratably in all assets remaining after payment of
liabilities, subject to prior distribution rights of preferred stock, if any,
then outstanding.
(b) Share Repurchase Programs—On
January 25, 2007, the Board of Directors authorized the repurchase of up to
$100,000 of the Company’s common stock. The Company repurchased 3,840 shares of
the Company’s common stock for a total of $100,000 from the January 2007
authorization and completed purchases from this authorization in June 2007. On
July 19, 2007, the Board of Directors approved an additional share repurchase
authorization to repurchase up to $200,000 of the Company’s common stock. The
Company repurchased 6,561 shares of the Company’s common stock for approximately
$200,000 from the July 2007 authorization and completed purchases from the July
2007 authorization in September 2007. On October 16, 2007, the Board of
Directors authorized an additional share repurchase authorization of up to
$300,000 of the Company’s common stock. Under the existing share repurchase
authorization, the Company has $280,100 available for repurchase as of March 31,
2008. No shares were repurchased during the first quarter of 2008.
Share repurchases under this authorization may be made through open market
transactions, negotiated purchase or otherwise, at times and in such amounts as
the Company and a committee of the Board deem appropriate. This share repurchase
authorization may be suspended, limited or terminated at any time without
notice.
(6)
Stock-Based Compensation
The Company
applies the provisions of SFAS 123R which establishes the accounting for
employee stock-based awards. The Company currently has three stock-based
compensation plans: the 2002 Option Plan (the 2002 Plan), the 2003 Equity
Incentive Plan (the 2003 Plan) and the 2003 Employee Stock Purchase Plan (the
ESPP) which are described under the caption “Stock-based Compensation” in the
notes to the Consolidated Financial Statements of the Company’s Form 10-K for
the year ended December 31, 2007.
The Company
granted new options to purchase 127 shares of common stock during the three
months ending March 31, 2008. The Company recognized compensation expense of $82
associated with the 2008 grants during the three months ended March 31, 2008.
The Company granted new options to purchase 225 shares of common stock during
the three months ending March 31, 2007. The Company recognized compensation
expense of approximately $72 associated with the 2007 grants during the three
months ended March 31, 2007. As of March 31, 2008, there was $894 of
unrecognized compensation expense associated with the options granted in 2008,
which is expected to be recorded over the weighted average remaining vesting
period of 3.8 years. The options granted in the three months ended March 31,
2008 had a weighted average grant-date fair value of $7.01 per option, as
determined by the Black-Scholes option pricing model using the following
assumptions:
Expected
volatility of stock
|
|
|
40
– 41 |
% |
Expected
life of options, in years
|
|
|
2.0
– 5.0 |
|
Risk-free
interest rate
|
|
|
2.4
– 3.1 |
% |
Expected
dividend yield on stock
|
|
|
1.4
– 2.0 |
% |
The Company
recorded $1,979 and $1,791 of total stock-based compensation expense for the
three months ended March 31, 2008 and March 31, 2007, respectively.
(7) Commitments and
Contingencies
(a) Purchase Commitments—The
Company will, from time to time, enter into limited purchase commitments for the
purchase of certain raw materials. Amounts committed under these programs are
not significant as of March 31, 2008.
(b) Securities Litigation—Between
October 7, 2005 and November 21, 2005, five complaints were filed against
Tempur-Pedic International and certain of its directors and officers in the
United States District Court for the Eastern District of Kentucky (Lexington
Division) purportedly on behalf of a class of shareholders who purchased
Tempur-Pedic International’s stock between April 22, 2005 and September 19, 2005
(the "Securities Law Action"). These actions were consolidated, and a
consolidated complaint was filed on February 27, 2006 asserting claims under
Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Lead plaintiffs
allege that certain of Tempur-Pedic International’s public disclosures regarding
its financial performance between April 22, 2005 and September 19, 2005 were
false and/or misleading. On December 7, 2006 lead plaintiffs were permitted to
file an amended complaint. The Company filed a Motion to Dismiss the Securities
Law Action and on March 28, 2008, the Court granted that motion, dismissing all
claims in the case with prejudice. The Court also entered final judgment in
favor of the Company and all other defendants on March 28, 2008. The plaintiffs
filed a notice of appeal from that judgment on April 24, 2008. The Company
continues to strongly believe that the Securities Law Action lacks merit, and
intends to continue to defend against these claims as necessary. However, due to
the inherent uncertainties of litigation, the Company cannot predict the outcome
of the Securities Law Action at this time, and can give no assurance that these
claims will not have a material adverse affect on our financial position or
results of operations. Accordingly, the Company cannot make an estimate of the
possible range of loss.
Derivative
Complaints—On November 10, 2005 and December 15, 2005, complaints were
filed in the state courts of Delaware and Kentucky, respectively, against
certain officers and directors of Tempur-Pedic International, purportedly
derivatively on behalf of the Company (the Derivative
Complaints). The Derivative Complaints assert that the named officers
and directors breached their fiduciary duties when they allegedly sold
Tempur-Pedic International’s securities on the basis of material non-public
information in 2005. In addition, the Delaware Derivative Complaint
asserts a claim for breach of fiduciary duty with respect to the disclosures
that also are the subject of the Securities Law Action described
above. On December 14, 2005 and January 26, 2006, respectively, the
Delaware court and Kentucky court stayed these derivative actions. Although the
Kentucky court action remains stayed, the Delaware court action stay was lifted
by the Court and the plaintiffs filed an amended complaint on April 5, 2007. The
Company responded by filing a motion to dismiss or stay the Delaware court
action on April 19, 2007. The Delaware court again stayed the
Delaware action on February 6, 2008. Tempur-Pedic International is also named as
a nominal defendant in the Derivative Complaints, although the actions are
derivative in nature and purportedly asserted on behalf of Tempur-Pedic
International. Tempur-Pedic International is in the process of
evaluating these claims. Accordingly, the Company cannot make an estimate of the
possible range of loss.
Antitrust
Action—On January 5, 2007, a purported class action was filed against the
Company in the United States District Court for the Northern District of
Georgia, Rome Division (Jacobs v. Tempur-Pedic International, Inc. and
Tempur-Pedic North America, Inc., or the “Antitrust Action”). The
Antitrust Action alleges violations of federal antitrust law arising from the
pricing of Tempur-Pedic mattress products by Tempur-Pedic North America and
certain distributors. The action alleges a class of all purchasers of
Tempur-Pedic mattresses in the United States since January 5, 2003, and seeks
damages and injunctive relief. Count Two of the complaint was dismissed by the
court on June 25, 2007, based on a motion filed by the Company. Following a
decision issued by the United States Supreme Court in Leegin Creative Leather Prods., Inc.
v. PSKS, Inc. on June 28, 2007, the Company filed a motion to dismiss the
remaining two counts of the Antitrust Action on July 10, 2007. On December 11,
2007, that motion was granted and, as a result, judgment was entered in favor of
the Company and the plaintiffs’ complaint was dismissed with prejudice. On
December 21, 2007, the Plaintiffs filed a “Motion to Alter or Amend Judgment,”
which has been fully briefed. On May 1, 2008, that motion was denied. The
deadline for plantiffs to appeal the judgement is June 2, 2008. The Company
continues to strongly believe that the Antitrust Action lacks merit, and intends
to defend against the claims vigorously. However, due to the inherent
uncertainties of litigation, the Company cannot predict the outcome of the
Antitrust Action at this time, and can give no assurance that these claims will
not have a material adverse affect on our financial position or results of
operation. Accordingly, the Company cannot make an estimate of the possible
range of loss.
The Company
is involved in various other legal proceedings incidental to the operations of
its business. The Company believes that the outcome of all such pending legal
proceedings in the aggregate will not have a materially adverse affect on its
business, financial condition, liquidity, or operating results.
(8)
Income Taxes
The Company’s
effective tax rate for the three months ended March 31, 2008 was 34.5%.
For the same period in 2007, the effective tax rate was 36.1%. The decrease in
the effective tax rate is primarily attributable to reduced local statutory tax
rates in various foreign jurisdictions.
Reconciling
items between the federal statutory income tax rate of 35.0% and the effective
tax rate include certain foreign tax rate differentials, state and local income
taxes, valuation allowances on certain net operating losses, foreign income
currently taxable in the U.S., the production activities deduction, and certain
other permanent differences.
At March 31,
2008, Tempur-Pedic International had undistributed earnings of $10,076 from its
foreign subsidiaries determined under U.S. tax principles as of November 1, 2002
related to the period prior to the acquisition of Tempur World, Inc. by
Tempur-Pedic International translated into U.S. dollars at the applicable
exchange rate on March 31, 2008. No provisions have been made for U.S. income
taxes or foreign withholding taxes on the remaining $10,076 of undistributed
earnings, as these earnings are considered indefinitely reinvested. In addition,
Tempur-Pedic International had remaining undistributed earnings from its foreign
subsidiaries determined under U.S. GAAP for the period from November 1, 2002
through March 31, 2008 of $205,524. No provisions have been made for
U.S. income taxes or foreign withholding taxes on the remaining $205,524 of
undistributed earnings, as these earnings are considered indefinitely
reinvested.
On October
24, 2007, the Company received income tax assessments from the Danish Tax
Authority with respect to 2001, 2002 and 2003 tax years. The tax
assessments relate to the royalty paid by one of Tempur-Pedic International’s
U.S. subsidiaries to Tempur-Pedic International’s Danish subsidiary. The
Danish Tax Authority believes the amount of the royalty should have been at a
higher rate than was actually paid and this position could apply to all
subsequent years. On January 23, 2008 the Company filed timely complaints
with the Danish National Tax Tribunal denying the tax assessments. The
National Tax Tribunal formally agreed to place the Danish tax litigation on hold
pending the outcome of a Bilateral Advance Pricing Agreement (“Bilateral APA”)
between the United States and the Danish Tax Authority. A Bilateral APA
involves an agreement between the U.S. Internal Revenue Service (IRS) and the
taxpayer, as well as a negotiated agreement with one or more foreign competent
authorities under applicable income tax treaties. The Company is preparing
a formal Bilateral APA application and supporting analyses for filing with the
IRS and the Danish Tax Authority. The Company currently believes it has
meritorious defenses to the assessments and will reactivate the litigation
regarding the assessments in the Danish courts if an agreement cannot be reached
through the Bilateral APA process. However, there is a reasonable
possibility that the amount of unrecognized tax benefits relating to this matter
may change during the next 12 months. An estimate of the amount of such
change cannot be made at this time. There have been no significant changes
to the status of any other tax examinations during the quarter ended March 31,
2008.
With a few
exceptions, the Company is no longer subject to U.S. federal, state/local, or
non-U.S. income tax examinations by tax authorities for years prior to 2004,
2003 and 2000, respectively.
(9)
Earnings Per Common Share
|
|
Three
Months Ended
|
|
|
|
March
31,
|
|
|
|
2008
|
|
|
2007
|
|
Numerator:
|
|
|
|
|
|
|
Net
income
|
|
$ |
13,514 |
|
|
$ |
29,780 |
|
|
|
|
|
|
|
|
|
|
Denominator:
|
|
|
|
|
|
|
|
|
Denominator
for basic earnings per common share-
weighted
average shares
|
|
|
74,591 |
|
|
|
83,947 |
|
Effect
of dilutive securities:
|
|
|
|
|
|
|
|
|
Employee
stock options
|
|
|
597 |
|
|
|
1,828 |
|
Denominator
for basic earnings per common share-adjusted
weighted average shares
|
|
|
75,188 |
|
|
|
85,775 |
|
|
|
|
|
|
|
|
|
|
Basic
earnings per common share
|
|
$ |
0.18 |
|
|
$ |
0.35 |
|
|
|
|
|
|
|
|
|
|
Diluted
earnings per common share
|
|
$ |
0.18 |
|
|
$ |
0.35 |
|
|
|
|
|
|
|
|
|
|
The Company
excluded 2,104 and 103 shares issuable upon exercise of outstanding stock
options for the three months ended March 31, 2008 and 2007, respectively, from
Diluted earnings per common share computation because their exercise price
was greater than the average market price of Tempur-Pedic International’s common
stock or if they were otherwise anti-dilutive.
(10)
Business Segment Information
The Company
operates in two business segments: Domestic and International. These reportable
segments are strategic business units that are managed separately based on the
fundamental differences in their operations. The Domestic segment consists of
the two U.S. manufacturing facilities, whose customers include the U.S.
distribution subsidiary and in certain third party distributors in North
America. The International segment consists of the manufacturing facility in
Denmark, whose customers include all of the distribution subsidiaries and third
party distributors outside the Domestic segment. The Company evaluates segment
performance based on Net sales and Operating income. Certain prior period
amounts have been reclassified to conform to 2008 presentation. The
reclassifications relate to the Company’s corporate office operating expenses
and certain amounts for goodwill and other assets that are carried at the
holding company level which are included in the Domestic operating
segment.
The following
table summarizes Total assets by segment:
|
|
March
31,
|
|
|
December
31,
|
|
|
|
2008
|
|
|
2007
|
|
Total
assets:
|
|
|
|
|
|
|
Domestic
|
|
$ |
607,350 |
|
|
$ |
608,346 |
|
International
|
|
|
359,612 |
|
|
|
339,757 |
|
Intercompany
eliminations
|
|
|
(146,327 |
) |
|
|
(141,671 |
) |
|
|
$ |
820,635 |
|
|
$ |
806,432 |
|
The following
tables summarize other segment information:
|
|
Three
Months Ended
|
|
|
|
March
31,
|
|
|
|
2008
|
|
|
2007
|
|
Net
sales from external customers:
|
|
|
|
|
|
|
Domestic
|
|
$ |
147,918 |
|
|
$ |
175,478 |
|
International
|
|
|
99,304 |
|
|
|
90,554 |
|
|
|
$ |
247,222 |
|
|
$ |
266,032 |
|
|
|
|
|
|
|
|
|
|
Inter-segment
sales:
|
|
|
|
|
|
|
|
|
Domestic
|
|
$ |
— |
|
|
$ |
— |
|
International
|
|
|
659 |
|
|
|
964 |
|
Intercompany
eliminations
|
|
|
(659 |
) |
|
|
(964 |
) |
|
|
$ |
— |
|
|
$ |
— |
|
|
|
|
|
|
|
|
|
|
Operating
income:
|
|
|
|
|
|
|
|
|
Domestic
|
|
$ |
3,737 |
|
|
$ |
29,374 |
|
International
|
|
|
25,596 |
|
|
|
24,380 |
|
|
|
$ |
29,333 |
|
|
$ |
53,754 |
|
|
|
|
|
|
|
|
|
|
Depreciation
and amortization (excluding
stock-based compensation
amortization):
|
|
|
|
|
|
|
|
|
Domestic
|
|
$ |
5,606 |
|
|
$ |
5,681 |
|
International
|
|
|
2,728 |
|
|
|
2,964 |
|
|
|
$ |
8,334 |
|
|
$ |
8,645 |
|
|
|
|
|
|
|
|
|
|
The following
table sets forth Net sales by significant product group:
|
|
Three
Months Ended
March
31,
|
|
|
|
2008
|
|
|
2007
|
|
Mattresses
|
|
$
|
168,050
|
|
|
$
|
185,007
|
|
Pillows
|
|
|
31,616
|
|
|
|
34,877
|
|
All
other
|
|
|
47,556
|
|
|
|
46,148
|
|
|
|
$
|
247,222
|
|
|
$
|
266,032
|
|
(11)
Restructuring Activities
During the
quarter ended March 31, 2008 the Company reduced headcount in the U.S. and
as a result, recorded a charge of approximately $600 relating to one time
employee termination costs.
|
MANAGEMENT’S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS
|
The following
discussion and analysis should be read in conjunction with the Condensed
Consolidated Financial Statements and accompanying notes included in this Form
10-Q. The forward-looking statements in this discussion regarding the mattress
and pillow industries, our expectations regarding our future performance,
liquidity and capital resources and other non-historical statements in this
discussion include numerous risks and uncertainties, as described under “Special
Note Regarding Forward-Looking Statements” and “Risk Factors” elsewhere in
this quarterly report on Form 10-Q and in our annual report on Form 10-K. Our
actual results may differ materially from those contained in any forward-looking
statements. Except as may be required by law, we undertake no obligation to
publicly update or revise any of the forward-looking statements contained
herein.
Executive
Overview
General—We are
the leading manufacturer, marketer and distributor of premium mattresses and
pillows which we sell in approximately 80 countries globally under the
TEMPUR® and
Tempur-Pedic® brands.
We believe our premium mattresses and pillows are more comfortable than standard
bedding products because our proprietary pressure-relieving TEMPUR® material is
temperature sensitive, has a high density and conforms to the body to
therapeutically align the neck and spine, thus reducing neck and lower back
pain, two of the most common complaints about other sleep surfaces.
Business Segment
Information—We have two reportable business segments: Domestic and
International. These reportable segments are strategic business units that are
managed separately based on the fundamental differences in their geographies.
The Domestic operating segment consists of our U.S. manufacturing facilities,
whose customers include our U.S. distribution subsidiary and certain third party
distributors in North America. The International segment consists of our
manufacturing facility in Denmark, whose customers include all of our
distribution subsidiaries and third party distributors outside the Domestic
operating segment. We evaluate segment performance based on Net sales and
Operating income. For the purpose of this Management’s Discussion and Analysis
of Financial Condition and Results of Operations, our Corporate office operating
expenses and certain amounts for goodwill and other assets that are carried at
the holding company level are included in the Domestic operating
segment.
Strategy
and Outlook
We believe we
are the industry leader in terms of profitability, and our long-term goal is
also to become the world’s largest bedding company in terms of revenue. In order
to achieve this goal, we expect to continue to pursue certain key strategies in
2008:
|
•
|
|
Maintain
our focus on premium mattresses and pillows and to regularly introduce new
products.
|
|
•
|
|
Invest
in increasing our global brand awareness through targeted marketing and
advertising campaigns that further associate our brand name with better
overall sleep and premium quality
products.
|
|
•
|
|
Extend
our presence and improve our account productivity in both the Domestic and
International Retail segments.
|
|
•
|
|
Invest
in our operating infrastructure to meet the requirements of our growing
business, including investments in our research and development
capabilities.
|
Results
of Operations
A
summary of our results for the three months ended March 31, 2008 includes the
following:
|
•
|
|
Earnings
per share (EPS) decreased to $0.18 per diluted common share in the first
quarter of 2008 as compared to $0.35 per diluted common share in the first
quarter of 2007.
|
|
•
|
|
Net
sales declined 7.1% to $247.2 million in the first quarter of 2008 from
$266.0 million in the first quarter of 2007. Net sales in the Domestic
segment declined 15.7%, while International segment Net sales increased
9.7%. On a constant currency basis, International segment Net sales
decreased 2.6%.
|
|
•
|
|
The
Company generated $24.6 million of cash from operating activities,
compared to $28.6 million for the first quarter of
2007.
|
($
in millions, except earnings per share)
|
|
Three
Months Ended
March
31,
|
|
|
|
2008
|
|
|
2007
|
|
Net
sales
|
|
$ |
247.2 |
|
|
|
100
|
% |
|
$ |
266.0 |
|
|
|
100
|
% |
Cost
of sales
|
|
|
139.1 |
|
|
|
56.3 |
|
|
|
138.3 |
|
|
|
52.0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross
profit
|
|
|
108.1 |
|
|
|
43.7 |
|
|
|
127.7 |
|
|
|
48.0 |
|
Selling
and marketing expenses
|
|
|
53.1 |
|
|
|
21.5 |
|
|
|
48.5 |
|
|
|
18.2 |
|
General
and administrative expenses and other
|
|
|
25.7 |
|
|
|
10.3 |
|
|
|
25.4 |
|
|
|
9.6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating
income
|
|
|
29.3 |
|
|
|
11.9 |
|
|
|
53.8 |
|
|
|
20.2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest
expense, net
|
|
|
(7.7
|
) |
|
|
(3.1
|
) |
|
|
(6.9
|
) |
|
|
(2.6
|
) |
Other
expense, net
|
|
|
(1.0
|
) |
|
|
(0.4
|
) |
|
|
(0.3
|
) |
|
|
(0.1
|
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income
before income taxes
|
|
|
20.6 |
|
|
|
8.4 |
|
|
|
46.6 |
|
|
|
17.5 |
|
Income
tax provision
|
|
|
7.1 |
|
|
|
2.9 |
|
|
|
16.8 |
|
|
|
6.3 |
|
Net
income
|
|
$ |
13.5 |
|
|
|
5.5
|
% |
|
$ |
29.8 |
|
|
|
11.2
|
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings
per common share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
$ |
0.18 |
|
|
|
|
|
|
$ |
0.35 |
|
|
|
|
|
Diluted
|
|
$ |
0.18 |
|
|
|
|
|
|
$ |
0.35 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash
dividend per common share
|
|
$ |
0.08 |
|
|
|
|
|
|
$ |
0.06 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
average common shares outstanding, in thousands:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
74,591 |
|
|
|
|
|
|
|
83,947 |
|
|
|
|
|
Diluted
|
|
|
75,188 |
|
|
|
|
|
|
|
85,775 |
|
|
|
|
|
Three
Months Ended March 31, 2008 Compared with Three Months Ended March 31,
2007
We sell our
premium mattresses and pillows through four distribution channels: Retail,
Direct, Healthcare, and Third party. The Retail channel sells to furniture and
bedding, specialty and department stores. The Direct channel sells directly to
consumers. The Healthcare channel sells to hospitals, nursing homes, healthcare
professionals and medical retailers. The Third party channel sells to
distributors in countries where we do not operate our own wholly-owned
subsidiaries. The following table sets forth Net sales information, by
channel:
|
CONSOLIDATED
|
|
DOMESTIC
|
|
INTERNATIONAL
|
|
|
Three
Months Ended
|
|
Three
Months Ended
|
|
Three
Months Ended
|
|
|
March
31,
|
|
March
31,
|
|
March
31,
|
|
(Millions)
|
2008
|
|
2007
|
|
2008
|
|
2007
|
|
2008
|
|
2007
|
|
Retail
|
|
$ |
207.9 |
|
|
$ |
219.0 |
|
|
$ |
129.1 |
|
|
$ |
150.0 |
|
|
$ |
78.8 |
|
|
$ |
69.0 |
|
Direct
|
|
|
12.8 |
|
|
|
21.8 |
|
|
|
10.7 |
|
|
|
19.3 |
|
|
|
2.1 |
|
|
|
2.5 |
|
Healthcare
|
|
|
12.2 |
|
|
|
11.7 |
|
|
|
3.8 |
|
|
|
3.2 |
|
|
|
8.4 |
|
|
|
8.5 |
|
Third
Party
|
|
|
14.3 |
|
|
|
13.5 |
|
|
|
4.3 |
|
|
|
3.0 |
|
|
|
10.0 |
|
|
|
10.5 |
|
|
|
$ |
247.2 |
|
|
$ |
266.0 |
|
|
$ |
147.9 |
|
|
$ |
175.5 |
|
|
$ |
99.3 |
|
|
$ |
90.5 |
|
A summary
of Net sales by product is set forth below:
|
CONSOLIDATED
|
|
DOMESTIC
|
|
INTERNATIONAL
|
|
|
Three
Months Ended
|
|
Three
Months Ended
|
|
Three
Months Ended
|
|
|
March
31,
|
|
March
31,
|
|
March
31,
|
|
(Millions)
|
2008
|
|
2007
|
|
2008
|
|
2007
|
|
2008
|
|
2007
|
|
Net
sales:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Mattresses
|
|
$ |
168.1 |
|
|
$ |
185.0 |
|
|
$ |
106.9 |
|
|
$ |
130.5 |
|
|
$ |
61.2 |
|
|
$ |
54.5 |
|
Pillows
|
|
|
31.6 |
|
|
|
35.0 |
|
|
|
13.1 |
|
|
|
15.7 |
|
|
|
18.5 |
|
|
|
19.3 |
|
Other
|
|
|
47.5 |
|
|
|
46.0 |
|
|
|
27.9 |
|
|
|
29.3 |
|
|
|
19.6 |
|
|
|
16.7 |
|
|
|
$ |
247.2 |
|
|
$ |
266.0 |
|
|
$ |
147.9 |
|
|
$ |
175.5 |
|
|
$ |
99.3 |
|
|
$ |
90.5 |
|
Net sales. Net
sales for the three months ended March 31, 2008 decreased to $247.2 million from
$266.0 million for the same period in 2007, a decrease of $18.8 million, or
7.1%. The primary area of sales weakness was in the U.S. The U.S. macroeconomic
environment deteriorated during the quarter, which contributed to what we
believe to be a slowdown in the mattress industry. Consolidated Mattress sales
decreased $17.0 million, or 9.2%. For the three months ended March
31, 2008, our Retail channel Net sales decreased to $207.9 million from $219.0
million for the same period in 2007, a decrease of $11.1 million, or
5.1%.
Consolidated
pillow sales decreased approximately $3.3 million, or 9.4%, from the first
quarter of 2007, primarily in the Domestic segment. This decrease was primarily
related to the slowdown in the U.S. economy. Consolidated Other, which includes
adjustable bedbases, foundations and other related products, increased $1.4
million, or 3.1%. This increase was driven by our increased focus on
adjustable bed base attach rates across the world, which are improving despite
the economic environment.
Domestic.
Domestic Net sales for the three months ended March 31, 2008 decreased to $147.9
million from $175.5 million for the same period in 2007, a decrease of $27.6
million, or 15.7%. Our Domestic Retail channel contributed $129.1 million in Net
sales for the three months ended March 31, 2008 for a decrease of $20.9 million,
or 13.9%, for the same period in 2007. We believe that the macroeconomic
environment impacted our Domestic Retail channel during the first quarter. We
believe that traffic in our Domestic Retail channel was slower, and that many
consumers are deferring high-end product purchases. As a result, domestic
mattress sales in the first quarter of 2008 decreased $23.6 million, or 18.1%,
over the same period in 2007. Pillow sales decreased $2.7 million, or 16.9%. Net
sales in the Direct channel decreased by $8.6 million, or 44.7%. We believe that
the macroeconomic environment also negatively impacted Net sales in the Direct
channel. Our Healthcare channel Net sales increased by $0.7 million, or 20.5%,
related to strategic relationships with healthcare companies who market joint
product offerings through their established distribution networks.
International.
International Net sales for the three months ended March 31, 2008 increased to
$99.3 million from $90.5 million for the same period in 2007, an increase of
$8.8 million, or 9.7%. The increase was driven by favorable foreign exchange
rates. On a constant currency basis, our International sales declined
approximately 2.6%. Our International segment was primarily impacted by
macroeconomic factors in certain key European markets. The International Retail
channel increased $9.8 million, or 14.2%, for the three months ended March 31,
2008. Our Direct channel sales decreased 15.9%. Additionally, Third party Net
sales decreased 5.3% and the Healthcare channel Net sales decreased
1.3%. International mattress sales in the first quarter of 2008
increased $6.6 million, or 12.2%, over the first quarter of 2007. Pillow sales
for the first quarter of 2008 decreased $0.6 million, or 3.1%, as compared to
the first quarter of 2007.
Gross profit.
Gross profit for the three months ended March 31, 2008 decreased to $108.1
million from $127.7 million for the same period in 2007, a decrease of $19.6
million, or 15.3%. Several factors impacted our Gross profit margin during the
quarter. These factors are identified and discussed below in the respective
segment discussions.
Domestic.
Domestic Gross profit for
the three months ended March 31, 2008 decreased to $53.6 million from $75.5
million for the same period in 2007, a decrease of $21.8 million, or
28.9%. The Gross profit margin in our Domestic segment was 36.3% and
43.0% for the three months ended March 31, 2008 and March 31, 2007,
respectively. For the three months ended March 31, 2008, the Gross profit margin
for our Domestic segment was impacted by lower than anticipated sales, an
inflationary cost environment and higher sales returns. The combination of
declines in the Direct channel, raw material cost inflation and lower volumes
resulted in a lower gross profit margin. Domestic Cost of sales for
the three months ended March 31, 2008 decreased to $94.3 million from $100.0
million for the same period in 2007, a decrease of $5.7 million, or
5.7%.
International.
International Gross profit for the three months
ended March 31, 2008 increased to $54.5 million from $52.2 million for the same
period in 2007, an increase of $2.3 million, or 4.3%. The Gross profit margin in
our International segment was 54.8% and 57.6% for the three months ended March
31, 2008 and March 31, 2007, respectively. The Gross profit margin for our
International segment was primarily impacted by an inflationary cost
environment. Our International Cost of sales for the three months ended March
31, 2008 increased to $44.9 million from $38.3 million for the same period in
2007, an increase of $6.5 million, or 16.9%.
Selling and marketing
expenses. Selling and marketing expenses
include advertising and media production; other marketing materials such as
catalogs, brochures, videos, product samples, direct customer mailings and point
of purchase materials; and sales force compensation and customer service. We
also include in Selling and marketing expenses certain new product development
costs, including market research and testing for new products. In the first
quarter of 2008, Selling and marketing expenses increased to $53.1 million for
the three months ended March 31, 2008 as compared to $48.5 million for the three
months ended March 31, 2007. Selling and marketing expenses as a percentage of
Net sales were 21.5% and 18.2% for the three months ended March 31, 2008 and
March 31, 2007, respectively. When sales trends deteriorated during
the three months ended March 31, 2008, much of our cost structure was
in place and we were unable to take actions to reduce our selling and marketing
costs to match our reduced sales levels. We have taken actions to align Selling
and marketing expenses with the revised sales expectations.
General and
administrative and other expenses. General and administrative
expenses include management salaries, information technology, professional fees,
depreciation of furniture and fixtures, leasehold improvements and computer
equipment, expenses for finance, accounting, human resources and other
administrative functions, and research and development costs associated with our
new product developments. General and administrative and other expenses
increased to $25.7 million for the three months ended March 31, 2008 as compared
to $25.4 million for the three months ended March 31, 2007, an increase of $0.2
million, or 0.6%. General and administrative and other expenses included a one
time charge for restructuring related to headcount reductions for the three
months ended March 31, 2008. General and administrative and other expenses as a
percentage of Net sales was 10.3% and 9.6% for the three months ended March 31,
2008 and March 31, 2007, respectively. When sales trends deteriorated during the
quarter ended March 31, 2008, much of our cost structure was in place and we
were unable to take actions to reduce our General and administrative and other
expenses to reflect our revised sales levels. We have taken actions to align
General and administrative and other expenses with revised sales
expectations.
Interest expense,
net. Interest expense, net, includes the interest costs associated with
our borrowings and the amortization of deferred financing costs related to those
borrowings. Interest expense, net, increased to $7.7 million for the three
months ended March 31, 2008, as compared to $6.9 million for the three months
ended March 31, 2007, an increase of $0.8 million, or 12.1%. The increase in
interest expense is primarily attributable to the increase in our total
Long-term debt levels partially offset by a decreases in our interest
rates.
Income tax
provision. Our Income tax
provision includes income taxes associated with taxes currently payable
and deferred taxes and includes the impact of net operating losses for certain
of our foreign operations. Our effective income tax rates for the three months
ended March 31, 2008 and for the three months ended March 31, 2007 differed from
the federal statutory rate principally because of certain foreign tax rate
differentials, state and local income taxes, valuation allowances on certain net
operating losses and the production activities deduction.
Our
effective tax rate for the three months ended March 31, 2008 was
34.5%. For the same period in 2007, the effective tax rate was
36.1%. The decrease in the effective tax rate is primarily
attributable to recent reductions in statutory tax rates in certain taxing
jurisdictions.
On
October 24, 2007, we received income tax assessments from the Danish Tax
Authority with respect to 2001, 2002 and 2003 tax years. The tax
assessments relate to the royalty paid by one of our U.S. companies to our
Danish subsidiary. The Danish Tax Authority believes the amount of the
royalty should have been at a higher rate than was actually paid and this
position could apply to all subsequent years. On January 23, 2008 we filed
timely complaints with the Danish National Tax Tribunal denying the tax
assessments. The National Tax Tribunal formally agreed to place the Danish
tax litigation on hold pending the outcome of a Bilateral Advance Pricing
Agreement (Bilateral APA) between the United States and the Danish Tax
Authority. A Bilateral APA involves an agreement between the Internal
Revenue Service (IRS) and the
taxpayer,
as well as a negotiated agreement with one or more foreign competent authorities
under applicable income tax treaties. We are preparing a formal Bilateral
APA application and supporting analyses for filing with the IRS and the Danish
Tax Authority. We currently believe that we have meritorious defenses to
the assessments and will reactivate our litigation regarding the assessments in
the Danish courts if an agreement cannot be reached through the Bilateral APA
process. However, there is a reasonable possibility that the amount of
unrecognized tax benefits relating to this matter may change during the next 12
months. An estimate of the amount of such change cannot be made at this
time. There have been no significant changes to the status of any other
unrecognized tax benefits during the quarter ended March 31, 2008.
Liquidity
and Capital Resources
Liquidity
Our principal
sources of funds are cash flows from operations and borrowings. Our principal
uses of funds consist of capital expenditures, payments of principal and
interest on our debt facilities, payments of dividends to our shareholders and
share repurchases from time to time pursuant to a share repurchase program. At
March 31, 2008, we had working capital of $217.1 million including Cash and cash
equivalents of $46.6 million as compared to working capital of $200.0 million
including $33.3 million in Cash and cash equivalents as of December 31,
2007. Working capital increased 8.6% as of March 31, 2008 compared to
December 31, 2007, primarily related to the increase in
Inventories.
Our cash flow
from operations decreased to $24.6 million for the three months ended March 31,
2008 as compared to $28.6 million for the three months ended March 31, 2007. The
decrease in operating cash flow for the period ending March 31, 2008, was
primarily a result of decreased Net income offset by favorable changes in
certain working capital accounts, primarily Accounts receivable. For the three
months ended March 31, 2008 inventory levels resulted in cash outflow of $2.3
million. The increase inventory levels are a result of lower than expected
sales. Inventories are expected to be a source of cash in the second
quarter assuming our expectations for sales trends are correct. We also plan to
improve Accounts receivable days outstanding and Accounts payable days
outstanding.
Net cash used
in investing activities increased to $4.4 million for the three months ended
March 31, 2008 as compared to $3.7 million for the three months ended
March 31, 2007, an increase of $0.8 million. The increase is primarily related
to increased capital expenditures and the acquisition of our former third party
distributor in New Zealand.
Cash flow
used by financing activities was $10.2 million for the three months ended March
31, 2008 as compared to $24.6 million for the three months ended March 31, 2007,
representing a decrease in cash flow used of $14.4 million. The decrease is
primarily related to a decrease in shares purchased under our share repurchase
program offset by $10.4 million in repayments, net of borrowings, in
2008.
Capital
Expenditures
Capital
expenditures totaled $2.8 million for the three months ended March 31, 2008 and
$2.4 million for the three months ended March 31, 2007. We currently expect our
2008 capital expenditures to be $14 million versus our prior forecast of $20
million. As part of our actions to align operating expenses with revised sales
expectations, we also evaluated our capital expenditure budget and deferred or
eliminated certain non-critical projects.
Debt
Service
Our long-term
debt decreased to $596.8 million as of March 31, 2008 from $601.8 million as of
December 31, 2007.
On April 1,
2008, Tempur Production redeemed all outstanding Series A Bonds in the amount of
$57.8 million. The redemption price plus accrued interest was funded
by a $58.0 million borrowing under the Domestic Revolver. In connection with the
redemption, the letter of credit supporting the Bonds was retired, resulting in
no additional indebtedness outstanding under the 2005 Senior Credit Facility. We
will record a pretax charge of $0.3 million as a Loss on extinguishment of debt
during the quarter ended June 30, 2008 related to the write-off of non-cash
deferred financing fees.
The interest
rate and certain fees that we pay in connection with the 2005 Senior Credit
Facility are subject to periodic adjustment based on changes in our consolidated
leverage ratio.
Stockholders’
Equity
Share Repurchase
Program— On January 25, 2007, our Board of Directors
authorized the repurchase of up to $100.0 million of our common stock. We
repurchased 3,840,485 shares of our common stock for a total of $100.0 million
from the January 2007 authorization and completed purchases from this
authorization in June 2007. On July 19, 2007, our Board of Directors approved an
additional share repurchase authorization to repurchase up to $200.0 million of
our common stock. We repurchased 6,561,489 shares of our common stock for
approximately $200.0 million from the July 2007 authorization and completed
purchases from the July 2007 authorization in September 2007. On October 16,
2007, our Board of Directors authorized an additional share repurchase
authorization of up to $300.0 million of our common stock. Under the existing
share repurchase authorization, we have $280.1 million available for repurchase
as of March 31, 2008. No shares were repurchased during the first
quarter of 2008. Share repurchases under this authorization may be made through
open market transactions, negotiated purchase or otherwise, at times and in such
amounts as we deem appropriate. This share repurchase authorization may be
suspended, limited or terminated at any time without
notice.
Dividend Program—
In the first quarter of 2007, our Board of Directors approved an annual
cash dividend of $0.24 per common share annually, to be paid in quarterly
installments to the owners of our common stock. In the second quarter of 2007,
our Board of Directors increased the quarterly dividend to $0.08 per common
share. Our Board declared a first quarter 2008 dividend of $0.08 per common
share that was distributed on March 14, 2008 to stockholders of record as
of February 27, 2008. This annual cash dividend program may be limited,
suspended, or terminated at any time without prior
notice.
Factors
That May Affect Future Performance
General Business and Economic
Conditions – Our business may be affected by general business and
economic conditions that could have an impact on demand for our products. The
U.S. macroeconomic environment deteriorated during the quarter and contributed
to what we believe is a slowdown in the mattress industry. In addition, our
international segment experienced weakening consumer trends in several European
markets.
Managing Growth—We have grown
rapidly, with our Net sales increasing from $221.5 million in 2001 to $1,106.7
million in 2007 and $247.2 million for the three months ended March 31, 2008. In
the past, our growth has placed, and may continue to place, a strain on our
management, production, product distribution network, information systems and
other resources. In response to these challenges, management has continued to
invest in increased production capacity, enhanced operating and financial
infrastructure and information systems and continued expansion of the human
resources in our operations. Our expenditures for advertising and other
marketing-related activities are made as advertising rates are favorable to us,
as the continued growth in the business allows us the ability to invest in
building our brand, but may be affected by lower than planned sales or an
inflationary cost environment.
Gross Margins—Our gross
margin is primarily impacted by product and channel mix, volume incentives
offered to certain retail accounts, operational efficiency and the cost of raw
material. Overall product mix impacts our gross margins because mattresses
generally carry lower margins than our pillows and are sold with lower margin
products such as foundations and bed frames, and our overall product mix has
shifted to mattresses and other products over the last several years. Our
margins are also impacted by the growth in our Retail channel as sales in our
Retail channel are at wholesale prices whereas sales in our direct channel are
at retail prices. Our gross margin can also be impacted by our operational
efficiencies, including the particular levels of utilization at our three
manufacturing facilities. Future increases in raw material prices could have a
negative impact on our gross margin if we do not raise prices to cover increased
cost.
Competition—Participants in
the mattress and pillow industries compete primarily on price, quality, brand
name recognition, product availability and product performance. We compete with
a number of different types of mattress alternatives, including standard
innerspring mattresses, other foam mattresses, waterbeds, futons, air beds and
other air-supported mattresses. These alternative products are sold through a
variety of channels, including furniture and bedding stores, specialty bedding
stores, department stores, mass merchants, wholesale clubs, telemarketing
programs, television infomercials and catalogs.
Our
largest competitors have significant financial, marketing and manufacturing
resources and strong brand name recognition, and sell their products through
broad and well established distribution channels. Additionally, we believe that
a number of our significant competitors offer mattress products claimed to be
similar to our TEMPUR®
mattresses and pillows.
we
provide strong channel profits to our retailers and distributors which
management believes will continue to provide an attractive business model for
our retailers and discourage them from carrying competing lower-priced
products.
Significant Growth
Opportunities—We believe there are
significant opportunities to take market share from the innerspring
mattress industry as well as other sleep surfaces. Our market share of the
overall mattress industry is relatively small in terms of both dollars and
units, which we believe provides us with a significant opportunity for growth.
By expanding our brand awareness and offering superior sleep surfaces, we
believe consumers will continue to adopt our products at an increasing rate,
which should expand our market share. Our business may be affected by general
business and economic conditions that could have an impact on demand for our
products. We believe that the premium and specialty bedding categories that we
target will continue to grow at a faster rate than the overall mattress industry
and we believe we will continue to experience the benefits of this consumer
adoption.
Our
ability to take market share also depends on our ability to successfully launch
new products. In the past, we have seen retailers and consumers respond well to
our new product development and technological superiority. Over the next few
quarters, we will begin the most extensive new product launch in our history.
This launch will include new mattress models, advanced technological innovations
and new pillow concepts as well as an upgrade to the most widely distributed
mattress model in our lineup.
In
addition, by expanding distribution within our existing accounts, we believe we
have the opportunity to grow our business by expanding our sales force as
necessary and extending our product line. Expansion gives our salespeople fewer
stores to call on, resulting in more time spent with each retail location so
they can work with each retailer on merchandising, training and educating retail
associates about the benefits of our products. Additionally, by extending our
product line, we should be able to continue to expand the number of Tempur-Pedic
models offered at the retail store level which should lead to increased sales.
Based on this strategy we believe a focus on expanding distribution within our
existing accounts provides for continued growth opportunities and market share
gains.
Expanding
distribution into new stores is also a source of growth opportunities. Our
products are currently sold in approximately 6,450 furniture and bedding retail
stores in the U.S., out of a total of approximately 10,000 stores we have
identified as appropriate targets. Within this addressable market, our plan is
to increase our total penetration to a total of 7,000 to 8,000 over time. Our
products are also sold in approximately 5,060 furniture retail and department
stores outside the U.S., out of a total of approximately 7,000 stores that we
have identified as appropriate targets. We are continuing to develop products
that are responsive to consumer demand in our markets
internationally.
In
addition to these growth opportunities, management believes that we currently
supply only a small percentage of approximately 15,400 nursing homes and 5,000
hospitals in the U.S., with a collective bed count in excess of 2.7 million.
Clinical evidence indicates that our products are both effective and cost
efficient for the prevention and treatment of pressure ulcers, or bed sores, a
major problem for elderly and bed-ridden patients. We have recently begun
partnering with healthcare vendors in an indirect sales method whereby the
vendor integrates our product into their products, in order to improve patient
comfort and wellness.
Financial
Leverage—As of March 31, 2008, we had $597.1 million of total
Long-term debt outstanding, and our Stockholders’ Equity was $70.2 million.
Higher financial leverage makes us more vulnerable to general adverse
competitive, economic and industry conditions. We believe that operating margins
driven by Net sales resulting from volume and price, productivity improvements
and cost containment activities will enable us to continue to de-leverage. There
can be no assurance, however, that our business will generate sufficient cash
flow from operations or that future borrowings will be available under our 2005
Senior Credit Facility.
Exchange
Rates—As a multinational company, we conduct our business in a wide
variety of currencies and are therefore subject to market risk for changes in
foreign exchange rates. We use foreign exchange forward contracts to manage a
portion of the exposure to the risk of the eventual net cash inflows and
outflows resulting from foreign currency denominated transactions between
Tempur-Pedic subsidiaries and their customers and suppliers, as well as between
the Tempur-Pedic subsidiaries themselves. These hedging transactions may not
succeed in effectively managing our foreign currency exchange rate risk. See
“ITEM 3. Quantitative and Qualitative Disclosures About Market Risk—Foreign
Currency Exposures” under Part I of this report.
Foreign
currency exchange rate movements also create a degree of risk by affecting the
U.S. dollar value of sales made and costs incurred in foreign currencies. We do
not enter into hedging transactions to hedge this risk. Consequently,
our reported earnings and financial position could fluctuate materially as a
result of foreign exchange gains or losses. Our outlook assumes no significant
changes in currency values from current rates. Should currency rates change
sharply, our results could be negatively impacted. See “ITEM 3. Quantitative and
Qualitative Disclosures About Market Risk—Foreign Currency Exposures” under Part
I of this report.
Critical
Accounting Policies and Estimates
For a
discussion of our critical accounting policies and estimates, see “ITEM 7.
Management’s Discussion and Analysis of Financial Condition and Results of
Operations” in our Form 10-K for the year ended December 31, 2007. There have
been no material changes to our critical accounting policies and estimates in
2008.
Impact
of Recently Issued Accounting Pronouncements
See Note 2 in
the Notes to Condensed Consolidated Financial Statements in ITEM 1under
Part I of this report for a full description of recent accounting
pronouncements, including the expected dates of adoption and estimated effects
on results of operations and financial condition, which is incorporated herein
by reference.
|
QUANTITATIVE
AND QUALITATIVE DISCLOSURES ABOUT MARKET
RISK
|
Foreign
Currency Exposures
Our earnings,
as a result of our global operating and financing activities, are exposed to
changes in foreign currency exchange rates, which may adversely affect our
results of operations and financial position. Our current outlook assumes no
significant changes in currency values from current rates. Should currency rates
change sharply, our results could be negatively impacted.
We protect a
portion of our currency exchange exposure with foreign currency forward
contracts. A sensitivity analysis indicates the potential loss in fair value on
foreign currency forward contracts outstanding at March 31, 2008, resulting from
a hypothetical 10% adverse change in all foreign currency exchange rates against
the U.S. Dollar, is less than $0.1 million. Such losses would be largely offset
by gains from the revaluation or settlement of the underlying assets and
liabilities that are being protected by the foreign currency forward
contracts.
We do not
apply hedge accounting to the foreign currency forward contracts used to offset
currency-related changes in the fair value of foreign currency denominated
assets and liabilities. These contracts are marked-to-market through earnings at
the same time that the exposed assets and liabilities are remeasured through
earnings.
Interest
Rate Risk
We are
exposed to changes in interest rates. Our 2005 Senior Credit Facility is
variable-rate debt.
Interest rate
changes generally do not affect the market value of such debt but do impact the
amount of our interest payments and therefore, our future earnings and cash
flows, assuming other factors are held constant. On March 31, 2008, we had
variable-rate debt of approximately $595.8 million. Holding other variables
constant, including levels of indebtedness, a one hundred basis point increase
in interest rates on our variable-rate debt would cause an estimated
reduction in income before income taxes for the next year of approximately
$6.0 million.
An evaluation
was performed under the supervision and with the participation of our
management, including our Chief Executive Officer and Chief Financial Officer,
of the effectiveness of our disclosure controls and procedures, as defined in
Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as
amended, as of the end of the period covered by this report. Based on that
evaluation, our management, including our Chief Executive Officer and Chief
Financial Officer, concluded that our disclosure controls and procedures were
effective as of March 31, 2008 and designed to ensure that information required
to be disclosed by us in reports that we file or submit under the Exchange Act,
is recorded, processed, summarized and reported within the time periods
specified in the SEC’s rules and forms and that such information is accumulated
and communicated to our management, including our Chief Executive Officer and
Chief Financial Officer, as appropriate to allow timely decisions regarding
required disclosure.
During our
last fiscal quarter, there were no changes in our internal control over
financial reporting that have materially affected, or are reasonably likely to
materially affect, our internal control over financial reporting.
PART II
OTHER
INFORMATION
Securities Law
Action—Between October 7, 2005 and November 21, 2005, five complaints
were filed against Tempur-Pedic International and certain of its directors and
officers in the United States District Court for the Eastern District of
Kentucky (Lexington Division) purportedly on behalf of a class of shareholders
who purchased Tempur-Pedic International’s stock between April 22, 2005 and
September 19, 2005 (the "Securities Law Action"). These actions were
consolidated, and a consolidated complaint was filed on February 27, 2006
asserting claims under Sections 10(b) and 20(a) of the Securities Exchange Act
of 1934. Lead plaintiffs allege that certain of Tempur-Pedic International’s
public disclosures regarding its financial performance between April 22, 2005
and September 19, 2005 were false and/or misleading. On December 7, 2006 lead
plaintiffs were permitted to file an amended complaint. The Company filed a
Motion to Dismiss the Securities Law Action and on March 28, 2008, the Court
granted that motion, dismissing all claims in the case with prejudice. The Court
also entered final judgment in favor of the Company and all other defendants on
March 28, 2008. The plaintiffs filed a notice of appeal from that judgment on
April 24, 2008. The Company continues to strongly believe that the Securities
Law Action lacks merit, and intends to continue to defend against these claims
as necessary. However, due to the inherent uncertainties of litigation, the
Company cannot predict the outcome of the Securities Law Action at this time,
and can give no assurance that these claims will not have a material adverse
affect on our financial position or results of operations. Accordingly, the
Company cannot make an estimate of the possible range of loss.
Derivative
Complaints – On November 10, 2005 and December 15, 2005, complaints
were filed in the state courts of Delaware and Kentucky, respectively, against
certain officers and directors of Tempur-Pedic International, purportedly
derivatively on behalf of the Company (the Derivative
Complaints). The Derivative Complaints assert that the named officers
and directors breached their fiduciary duties when they allegedly sold
Tempur-Pedic International’s securities on the basis of material non-public
information in 2005. In addition, the Delaware Derivative Complaint
asserts a claim for breach of fiduciary duty with respect to the disclosures
that also are the subject of the Securities Law Action described
above. On December 14, 2005 and January 26, 2006, respectively, the
Delaware court and Kentucky court stayed these derivative actions. Although the
Kentucky court action remains stayed, the Delaware court action stay was lifted
by the Court and the plaintiffs filed an amended complaint on April 5, 2007. The
Company responded by filing a motion to stay or dismiss the Delaware court
action on April 19, 2007. The Delaware court again stayed the
Delaware action on February 6, 2008. Tempur-Pedic International is also named as
a nominal defendant in the Derivative Complaints, although the actions are
derivative in nature and purportedly asserted on behalf of Tempur-Pedic
International. Accordingly, we cannot make an estimate of the
possible ranges of loss.
Antitrust Action – On
January 5, 2007, a purported class action was filed against the Company in the
United States District Court for the Northern District of Georgia, Rome Division
(Jacobs v. Tempur-Pedic International, Inc. and Tempur-Pedic North America,
Inc., or the “Antitrust Action”). The Antitrust Action alleges violations
of federal antitrust law arising from the pricing of Tempur-Pedic mattress
products by Tempur-Pedic North America and certain distributors. The
action alleges a class of all purchasers of Tempur-Pedic mattresses in the
United States since January 5, 2003, and seeks damages and injunctive relief.
Count Two of the complaint was dismissed by the court on June 25, 2007, based on
a motion filed by the Company. Following a decision issued by the United States
Supreme Court in Leegin
Creative Leather Prods., Inc. v. PSKS, Inc. on June 28, 2007, we filed a
motion to dismiss the remaining two counts of the Antitrust Action on July 10,
2007. On December 11, 2007, that motion was granted and, as a result, judgment
was entered in favor of the Company and the plaintiffs’ complaint was dismissed
with prejudice. On December 21, 2007, the Plaintiffs filed a “Motion to Alter or
Amend Judgment,” which has been fully briefed. On May 1, 2008, that motion was
denied. The deadline for plantiffs to appeal the judgment is June 2, 2008. We
continue to strongly believe that the Antitrust Action lacks merit, and intend
to defend against the claims vigorously. However, due to the inherent
uncertainties of litigation, we cannot predict the outcome of the Antitrust
Action at this time, and can give no assurance that these claims will not have a
material adverse affect on our financial position or results of operation.
Accordingly, we cannot make an estimate of the possible ranges of
loss.
We are
involved in various other legal proceedings incidental to the operations of our
business. We believe that the outcome of all such pending legal proceedings in
the aggregate will not have a materially adverse effect on our business,
financial condition, liquidity, or operating results.
In addition to the
other information set forth in this quarterly report, you should carefully
consider the factors discussed under the heading, “Risk Factors” in Item IA of
Part I of our annual report on Form 10-K, some of which are updated below. These
risks are not the only ones facing the Company. Please also see “Special Note
Regarding Forward-Looking Statements” on page 3.
We
are subject to risks from our international operations, such as increased costs
and the potential absence of intellectual property protection, which could
impair our ability to compete and our profitability.
We
currently conduct international operations in approximately 80 countries,
and we continue to pursue additional international opportunities. We generated
approximately 40.2% of our Net sales from non-U.S. operations during the three
months ended March 31, 2008. Our international operations are subject to the
customary risks of operating in an international environment, including
complying with foreign laws and regulations and the potential imposition of
trade or foreign exchange restrictions, tariff and other tax increases,
fluctuations in exchange rates, inflation and unstable political situations, and
labor issues.
On October
24, 2007, the Company received an income tax assessment from the Danish Tax
Authority with respect to the 2001, 2002 and 2003 tax years. The
tax assessment relates to the royalty paid by one of our U.S. subsidiaries to
our Danish subsidiary and the position taken by the Danish Tax Authority could
apply to subsequent years. On January 23, 2008 we filed timely complaints
with the Danish National Tax Tribunal denying the tax assessments. The
National Tax Tribunal formally agreed to place the Danish tax litigation on hold
pending the outcome of a Bilateral Advance Pricing Agreement (Bilateral APA)
between the United States and the Danish Tax Authority. A Bilateral APA
involves an agreement between the Internal Revenue Service (IRS) and the
taxpayer, as well as a negotiated agreement with one or more foreign competent
authorities under applicable income tax treaties. We are preparing a
formal Bilateral APA application and supporting analyses for filing with the IRS
and the Danish Tax Authority. Management is currently evaluating the assessment.
The Company believes it has meritorious defenses to the proposed
adjustment and will oppose the assessment in the Danish
courts. However, there is a reasonable possibility under FIN 48 that
the amount of unrecognized tax benefits relating to this matter may change in
the next twelve months. An estimate of the amount of such change
cannot be made at this time.
An
increase in our product return rates or an inadequacy in our warranty reserves
could reduce our liquidity and profitability.
Part of
our Domestic marketing and advertising strategy in certain Domestic channels
focuses on providing up to a 120-day money back guarantee under which customers
may return their mattress and obtain a refund of the purchase price. For the
three months ended March 31, 2008, we had approximately $11.4 million in returns
for a return rate of approximately 6.5% of our Net sales in the U.S. As we
expand our sales, our return rates may not remain within our historical levels.
An increase in return rates could significantly impair our liquidity and
profitability. We also currently provide our customers with a limited, pro-rata
20-year warranty on mattresses sold in the U.S. and a limited 15-year warranty
on mattresses sold outside of the U.S. However, as we have only been selling
mattresses in significant quantities since 1992, and have released new products
in recent years, many are fairly early in their product life cycles. We also
provide 2-year to 3-year warranties on pillows.
Because
our products have not been in use by our customers for the full warranty period,
we rely on the combination of historical experience and product testing for the
development of our estimate for warranty claims. However, our actual level of
warranty claims could prove to be greater than the level of warranty claims we
estimated based on our products’ performance during product testing. If our
warranty reserves are not adequate to cover future warranty claims, their
inadequacy could have a material adverse effect on our liquidity and
profitability.
Our
leverage limits our flexibility and increases our risk of default.
As of March
31, 2008, we had $597.1 million in total Long-term debt outstanding. In
addition, as of March 31, 2008, our Stockholders’ Equity was $70.2 million.
Between October 2005 and March 31, 2008, we repurchased a total of $540.0
million in common stock pursuant to stock repurchase authorizations authorized
by our Board of Directors. We funded the repurchase in part through borrowings
under our 2005 Senior Credit Facility, which has substantially increased our
leverage.
Our Board
of Directors may authorize additional share repurchases in the future and we may
fund these repurchases with debt. On February 19, 2008 our Board of Directors
declared a first quarter 2008 dividend to stockholders of record as of February
27, 2008, which was distrubted on March 14, 2008.
Our degree of
leverage could have important consequences to our investors, such
as:
|
•
|
|
limiting
our ability to obtain in the future additional financing we may need to
fund future working capital, capital expenditures, product development,
acquisitions or other corporate requirements;
and
|
|
•
|
|
requiring
the dedication of a substantial portion of our cash flow from operations
to the payment of principal and interest on our debt, which will reduce
the availability of cash flow to fund working capital, capital
expenditures, product development, acquisitions and other corporate
requirements.
|
In addition,
the instruments governing our debt contain financial and other restrictive
covenants, which limit our operating flexibility and could prevent us from
taking advantage of business opportunities. In addition, our failure to comply
with these covenants may result in an event of default. If such event of default
is not cured or waived, we may suffer adverse effects on our operations,
business or financial condition, including acceleration of our
debt.
|
UNREGISTERED
SALES OF EQUITY SECURITIES AND USE OF
PROCEEDS
|
(a) Not
applicable.
(b) Not
applicable.
(c) Not
applicable.
|
DEFAULTS
UPON SENIOR SECURITIES
|
None
|
SUBMISSION
OF MATTERS TO A VOTE OF SECURITY
HOLDERS
|
None
(a) Not
applicable.
(b) Not
applicable.
The
following is an index of the exhibits included in this report:
10.1
|
|
|
Amended
and Restated Employment and Noncompetition Agreement dated as of March 5,
2008 between Tempur-Pedic International Inc. and Dale E. Williams.
(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
Incorporated
by reference from the Registrant’s Current Report on Form 8-K filed with
the Commission on March 7, 2008.
|
*
|
This
exhibit shall not be deemed “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (15 U.S.C. 78r), or otherwise
subject to the liabilities of that Section, nor shall it be deemed
incorporated by reference in any filings under the Securities Act of 1933,
as amended, or the Securities Exchange Act of 1934, as amended, whether
made before or after the date hereof and irrespective of any general
incorporation language in any filings.
|
|
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
TEMPUR-PEDIC
INTERNATIONAL INC.
|
|
|
|
|
(Registrant)
|
|
|
|
|
Date:
May 6, 2008
|
|
|
|
By:
|
|
/s/ DALE
E.
WILLIAMS
|
|
|
|
|
|
|
|
|
Dale
E. Williams
|
|
|
|
|
|
|
|
|
Executive
Vice President, Chief Financial Officer,
|
|
|
|
|
|
|
|
|
and
Secretary
|
exhibi102.htm
TEMPUR-PEDIC
INTERNATIONAL INC.
2003
EQUITY INCENTIVE PLAN
Stock
Option Agreement
Richard
Anderson
This
Agreement dated as of February 5, 2008, between Tempur-Pedic International Inc.,
a corporation organized under the laws of the State of Delaware (the “Company”), and the
individual identified below, residing at the address there set out (the “Optionee”).
1. Grant of
Option. Pursuant and subject to the Company’s 2003 Equity
Incentive Plan (as the same may be amended from time to time, the “Plan”), the
Company grants to the
Optionee an option (the “Option”) to purchase
from the Company all or any part
of a total of 100,000 shares (the “Optioned Shares”) of
the Company’s common stock, par value $0.01 per share (the “Stock”), at a price
of $20.02 per share. The Grant Date of this Option is January 29,
2008.
2. Character of
Option. This Option is not to be treated as an “incentive
stock option” within the meaning of Section 422 of the Internal Revenue Code of
1986, as amended.
3. Duration of
Option. Subject to the following sentence, this Option shall expire at
5:00 p.m. on ten years from the Grant Date. However, if the
Optionee’s employment with the Company and its
Affiliates ends before that date (including because the Optionee’s employer
ceases to be an Affiliate), this Option shall expire on
the earlier date specified in whichever of the following applies:
(a) If the
termination of the Optionee’s employment is on account of the optionee’s death
or disability, the first anniversary of the date the Optionee’s employment ends;
or
(b) If the
termination of the Optionee’s employment is due to any other reason, three (3)
months after the Optionee’s employment ends.
4. Exercise of
Option.
(a) Until
this Option expires, the Optionee may exercise it as to the number of Optioned
Shares identified in the table below, in full or in part, at any time on or
after the applicable exercise date or dates identified in the
table. However, during any period that this Option remains
outstanding after the Optionee’s employment with the Company and its Affiliates
ends, including because the Optionee’s employer ceases to be an Affiliate, the
Optionee may exercise it only to the extent it was exercisable immediately prior
to the end of the Optionee’s employment. The procedure for exercising
this Option is described in Section 7.1(e) of the Plan. The Optionee
may pay the exercise price due on exercise by delivering other shares of Stock
of equivalent Market Value provided the Optionee has owned such shares of Stock
for at least six months.
Number
of Shares
in Each Installment
|
Percentage
of
Optioned Shares
|
Initial
Exercise Date
for Shares in
Installment
|
25,000
|
25%
|
January
29, 2009
|
25,000
|
25%
|
January
29, 2010
|
25,000
|
25%
|
January
29, 2011
|
25,000
|
25%
|
January
29, 2012
|
(b) In lieu of the Change of Control provisions of Section 9 (a) -
(c) of the Plan, if (i) a Change of Control occurs and (ii) the Optionee’s
employment is terminated but not For Cause (as defined in the Optionee’s
Employment Agreement dated July 18, 2006) or if the Optionee resigns for Good
Reason (as defined in the Optionee’s Employment Agreement dated July 18, 2006)
within twelve (12) months after the occurrence of a Change of Control, the
Optionee’s next installment of 25,000 Optioned Shares will Accelerate as of the
date of his termination of employment.
5. Transfer of
Option. Except as provided in Section 6.4 of the Plan, this
Option may
not be transferred except by will or the laws of descent and distribution, and
during the Optionee’s lifetime, only the Optionee may exercise this
Option.
6. Incorporation of Plan
Terms. Except as otherwise provided herein in Section 4(b)
above, this Option is granted
subject to all of the applicable terms and provisions of the Plan, including but
not limited to the limitations on the Company’s obligation to
deliver Optioned Shares upon exercise set forth in Section 10 of the Plan,
“Settlement of Awards”. Capitalized terms used but not defined herein
shall have the meaning assigned under the Plan.
7. Miscellaneous. This
Agreement shall be construed and enforced in accordance with the laws of the
State of Delaware, without regard to the conflict of laws principles thereof,
and shall be binding upon and inure to the benefit of any successor or assign of
the Company and any
executor, administrator, trustee, guardian, or other legal representative of the
Optionee. This Agreement may be executed in one or more counterparts
all of which together shall constitute one instrument.
8. Tax
Consequences. The Company makes no representation or warranty
as to the tax treatment of this Option, including upon the exercise of this
Option or upon the Optionee’s sale or other disposition of the Optioned
Shares. The Optionee should rely on his/her own tax advisors for such
advice.
9. Certain Remedies.
(a) If at any
time within two years after termination of the Optionee’s employment with the
Company and its Affiliates any of the following occur:
(i) the
Optionee unreasonably refuses to comply with lawful requests for cooperation
made by the Company, its board of directors, or its Affiliates;
(ii) the
Optionee accepts employment or a consulting or advisory engagement with any
Competitive Enterprise of the Company or its Affiliates or the Optionee
otherwise engages in competition with the Company or its
Affiliates;
(iii) the
Optionee acts against the interests of the Company and its Affiliates, including
recruiting or employing, or encouraging or assisting the Optionee’s new employer
to recruit or employ an employee of the Company or any Affiliate without the
Company’s written consent;
(iv) the
Optionee fails to protect and safeguard while in his/her possession or control,
or surrender to the Company upon termination of the Optionee’s employment with
the Company or any Affiliate or such earlier time or times as the Company or its
board of directors or any Affiliate may specify, all documents, records, tapes,
disks and other media of every kind and description relating to the business,
present or otherwise, of the Company and its Affiliates and any copies, in whole
or in part thereof, whether or not prepared by the Optionee;
(v) the
Optionee solicits or encourages any person or enterprise with which the Optionee
has had business-related contact, who has been a customer of the Company or any
of its Affiliates, to terminate its relationship with any of them;
or
(vi) the
Optionee breaches any confidentiality obligations the Optionee has to the
Company or an Affiliate, the Optionee fails to comply with the policies and
procedures of the Company or its Affiliates for protecting confidential
information, the Optionee uses confidential information of the Company or its
Affiliates for his/her own benefit or gain, or the Optionee discloses or
otherwise misuses confidential information or materials of the Company or its
Affiliates (except as required by applicable law); then
(1) this
Option shall terminate and be cancelled effective as of the date on which the
Optionee entered into such activity, unless terminated or cancelled sooner by
operation of another term or condition of this Agreement or the
Plan;
(2) any stock
acquired and held by the Optionee pursuant to the exercise of this Option during
the Applicable Period (as defined below) may be repurchased by the Company at a
purchase price of $20.02 per share; and
(3) any gain
realized by the Optionee from the sale of stock acquired through the exercise of
this Option during the Applicable Period shall be paid by the Optionee to the
Company;
(b) The term
“Applicable
Period” shall
mean the period commencing on the later of the date of this Agreement or the
date which is one year prior to the Optionee’s termination of employment with
the Company or any Affiliate and ending two years from the Optionee’s
termination of employment with the Company or any Affiliate.
(c) The term
“Competitive
Enterprise”
shall mean a business enterprise that engages in, or owns or controls a
significant interest in, any entity that engages in, the manufacture, sale or
distribution of mattresses or pillows or other bedding products or other
products competitive with the Company’s products. Competitive
Enterprise shall include, but not be limited to, the entities set forth on
Appendix A hereto, which may be amended by the Company from time to time upon
notice to the Optionee. At any time the Optionee may request in
writing that the Company make a determination whether a particular enterprise is
a Competitive Enterprise. Such determination will be made within 14
days after the receipt of sufficient information from the Optionee about the
enterprise, and the determination will be valid for a period of 90 days from the
date of determination.
10. Right of Set
Off. By executing this Agreement, the Optionee consents to a
deduction from any amounts the Company or any Affiliate owes the Optionee from
time to time, to the extent of the amounts the Optionee owes the Company under
Section 9 above, provided that this set-off right may not be applied against
wages, salary or other amounts payable to the Optionee to the extent that the
exercise of such set-off right would violate any applicable law. If
the Company does not recover by means of set-off the full amount the Optionee
owes the Company, calculated as set forth above, the Optionee agrees to pay
immediately the unpaid balance to the Company upon the Company’s
demand.
11. Nature of
Remedies.
(a) The
remedies set forth in Sections 9 and 10 above are in addition to any
remedies available to the Company and its Affiliates in any non-competition,
employment, confidentiality or other agreement, and all such rights are
cumulative. The exercise of any rights hereunder or under any such
other agreement shall not constitute an election of remedies.
(b) The
Company shall be entitled to place a legend on any certificate evidencing any
stock acquired upon exercise of this Option referring to the repurchase right
set forth in Section 9(a) above. The Company shall also be
entitled to issue stop transfer instructions to the Company’s stock transfer
agent in the event the Company believes that any event referred to in
Section 9(a) has occurred or is reasonably likely to occur.
[Remainder of page intentionally left
blank]
In
Witness Whereof, the parties have executed this Agreement as of the date first above
written.
TEMPUR-PEDIC
INTERNATIONAL INC. |
|
|
|
|
|
|
|
|
|
By: |
|
|
/s/ Richard
Anderson |
February
14, 2008 |
|
Title: |
President
& Chief Executive Officer |
|
Signature
of Optionee |
Date |
|
Date: |
February
5, 2008 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Richard
Anderson
|
|
|
|
|
|
Name
of Optionee |
|
|
|
|
|
|
|
|
|
|
|
Optionee's
Address: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
exhibit311.htm
CERTIFICATION
OF CHIEF EXECUTIVE OFFICER PURSUANT TO
SECURITIES
EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a), AS ADOPTED PURSUANT TO
SECTION
302 OF THE SARBANES-OXLEY ACT OF 2002
I, H.
Thomas Bryant, certify that:
1. I have
reviewed this quarterly report on Form 10-Q of Tempur-Pedic International
Inc.;
2. Based
on my knowledge, this report does not contain any untrue statement of a material
fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading
with respect to the period covered by this report;
3. Based
on my knowledge, the financial statements, and other financial information
included in this report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and
for, the periods presented in this report;
4. The
registrant’s other certifying officer(s) and I are responsible for establishing
and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as
defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and
have:
(a)
Designed such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision, to ensure that
material information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly
during the period in which this report is being prepared;
(b)
Designed such internal control over financial reporting, or caused such internal
control over financial reporting to be designed under our supervision, to
provide reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles;
(c)
Evaluated the effectiveness of the registrant’s disclosure controls and
procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered
by this report based on such evaluation; and
(d)
Disclosed in this report any change in the registrant’s internal control over
financial reporting that occurred during the registrant’s most recent fiscal
quarter (the registrant’s fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the
registrant’s internal control over financial reporting; and
5. The
registrant’s other certifying officer(s) and I have disclosed, based on our most
recent evaluation of internal control over financial reporting, to the
registrant’s auditors and the audit committee of the registrant’s board of
directors (or persons performing the equivalent functions):
(a) All
significant deficiencies and material weaknesses in the design or operation of
internal control over financial reporting which are reasonably likely to
adversely affect the registrant’s ability to record, process, summarize and
report financial information; and
(b) Any
fraud, whether or not material, that involves management or other employees who
have a significant role in the registrant’s internal control over financial
reporting.
Date:
May 6, 2008
|
|
|
|
/s/ H.
THOMAS
BRYANT
|
|
|
|
|
H.
Thomas Bryant
|
|
|
|
|
President
and Chief Executive Officer
|
exhibit312.htm
CERTIFICATION
OF CHIEF FINANCIAL OFFICER PURSUANT TO
SECURITIES
EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a), AS ADOPTED PURSUANT TO
SECTION
302 OF THE SARBANES-OXLEY ACT OF 2002
I, Dale
E. Williams, certify that:
1. I have
reviewed this quarterly report on Form 10-Q of Tempur-Pedic International
Inc.;
2. Based
on my knowledge, this report does not contain any untrue statement of a material
fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading
with respect to the period covered by this report;
3. Based
on my knowledge, the financial statements, and other financial information
included in this report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and
for, the periods presented in this report;
4. The
registrant’s other certifying officer(s) and I are responsible for establishing
and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as
defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and
have:
(a)
Designed such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision, to ensure that
material information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly
during the period in which this report is being prepared;
(b)
Designed such internal control over financial reporting, or caused such internal
control over financial reporting to be designed under our supervision, to
provide reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles;
(c)
Evaluated the effectiveness of the registrant’s disclosure controls and
procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered
by this report based on such evaluation; and
(d)
Disclosed in this report any change in the registrant’s internal control over
financial reporting that occurred during the registrant’s most recent fiscal
quarter (the registrant’s fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the
registrant’s internal control over financial reporting; and
5. The
registrant’s other certifying officer(s) and I have disclosed, based on our most
recent evaluation of internal control over financial reporting, to the
registrant’s auditors and the audit committee of the registrant’s board of
directors (or persons performing the equivalent functions):
(a) All
significant deficiencies and material weaknesses in the design or operation of
internal control over financial reporting which are reasonably likely to
adversely affect the registrant’s ability to record, process, summarize and
report financial information; and
(b) Any
fraud, whether or not material, that involves management or other employees who
have a significant role in the registrant’s internal control over financial
reporting.
Date:
May 6, 2008
|
|
|
|
/s/ DALE
E.
WILLIAMS
|
|
|
|
|
Dale
E. Williams
|
|
|
|
|
Executive
Vice President, Chief Financial Officer,
|
|
|
|
|
and
Secretary
|
exhibit321.htm
CERTIFICATION
OF CHIEF EXECUTIVE OFFICER AND
CHIEF
FINANCIAL OFFICER PURSUANT TO
18
U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002
Each of
the undersigned hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, in his capacity as an
officer of Tempur-Pedic International Inc. (the “Company”), that, to his
knowledge, the Quarterly Report of the Company on Form 10-Q for the period ended
March 31, 2008, fully complies with the requirements of Section 13(a) or 15(d)
of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)) and that the
information contained in such report fairly presents, in all material respects,
the financial condition and results of operations of the Company. This written
statement is being furnished to the Securities and Exchange Commission as an
exhibit to such Form 10-Q. A signed original of this statement has been provided
to the Company and will be retained by the Company and furnished to the
Securities and Exchange Commission or its staff upon request.
|
|
|
|
|
|
|
|
|
Date:
May 6, 2008
|
|
|
|
By:
|
|
/s/ H.
THOMAS
BRYANT
|
|
|
|
|
|
|
|
|
H.
Thomas Bryant
|
|
|
|
|
|
|
|
|
President
and Chief Executive Officer
|
|
|
|
|
Date:
May 6, 2008
|
|
|
|
By:
|
|
/s/ DALE
E.
WILLIAMS
|
|
|
|
|
|
|
|
|
Dale
E. Williams
|
|
|
|
|
|
|
|
|
Executive
Vice President, Chief Financial Officer,
and
Secretary
|